27 September 2022
EMA/CHMP/685582/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 18-21 July 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) pandemic, and the associated EMA Business Continuity Plan (BCP), the meeting was held in-person with some members connected remotely (hybrid setting).

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 18-21 July 2022.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 20-23 June 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 11 July 2022.

The CHMP adopted the minutes of the June Plenary meeting as well as the minutes from the July PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. Exkivity - mobocertinib - EMEA/H/C/005621

Takeda Pharma A/S; Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Scope: Oral explanation

Action: Oral explanation to be held on 20 July 2022 at 09:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 11.11.2021.

An oral explanation was held on 20 July 2022. The presentation by the applicant focused on the clinical data in support of the application.

See 3.7

2.1.2. Lupkynis - voclosporin - EMEA/H/C/005256

Otsuka Pharmaceutical Netherlands B.V.; Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Scope: Possible oral explanation

Action: Oral explanation to be held on 20 July 2022 at 15:30

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 11.11.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.1.3. Nulibry - fosdenopterin - Orphan - EMEA/H/C/005378

Comharsa Life Sciences Ltd; treatment of molybdenum cofactor deficiency type A

Scope: Possible oral explanation

Action: Oral explanation to be held on 20 July 2022 at 11:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022, 20.04.2022. List of Questions adopted on 22.02.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.1.4. mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: Possible oral explanation

Action: Oral explanation to be held on 20 July 2022 at 17:00

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 11.11.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.5. Tezspire - tezepelumab - EMEA/H/C/005588

AstraZeneca AB; add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: Possible oral explanation

Action: Oral explanation to be held on 19 July 2022 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 14.10.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.1.6. Vabysmo - faricimab - EMEA/H/C/005642

Roche Registration GmbH; treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

Scope: Possible oral explanation

Action: Oral explanation to be held on 19 July 2022 at 14:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 14.10.2021.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Amvuttra - vutrisiran - Orphan - EMEA/H/C/005852

Alnylam Netherlands B.V.; treatment of hereditary transthyretin-mediated amyloidosis

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that vutrisiran is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 July 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.2. Celdoxome - doxorubicin hydrochloride - EMEA/H/C/005330

YES Pharmaceutical Development Services GmbH; treatment of breast cancer, treatment of ovarian cancer, treatment of multiple myeloma, treatment of AIDS related Kaposi's sarcoma

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on

28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 20 July 2022.

The summary of opinion was circulated for information.

3.1.3. Lupkynis - voclosporin - EMEA/H/C/005256

Otsuka Pharmaceutical Netherlands B.V.; Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 11.11.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that voclosporin is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 21 July 2022.

The summary of opinion was circulated for information.

3.1.4. ilLuzyce - lutetium (177lu) chloride - EMEA/H/C/005859

Billev Pharma Aps; is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

Scope: Opinion

Action: For adoption

Well-established use application (Article 10a of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.5. Mounjaro - tirzepatide - EMEA/H/C/005620

Eli Lilly Nederland B.V.; treatment of adults with type 2 diabetes mellitus

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tirzepatide is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.6. Nulibry - fosdenopterin - Orphan - EMEA/H/C/005378

Comharsa Life Sciences Ltd; treatment of molybdenum cofactor deficiency type A

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022, 20.04.2022. List of Questions adopted on 22.02.2022.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a positive opinion recommending the granting of a marketing

authorisation under exceptional circumstances by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that fosdenopterin is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.7. Opdualag - relatlimab / nivolumab - EMEA/H/C/005481

Bristol-Myers Squibb Pharma EEIG; indicated for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents (12 years and older and weighing at least 40 kg).

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that relatlimab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 21 July 2022.

The summary of opinion was circulated for information.

3.1.8. Tecvayli - teclistamab - PRIME - Orphan - EMEA/H/C/005865

Accelerated assessment

Janssen-Cilag International N.V.; treatment of relapsed or refractory multiple myeloma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 17.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus, together with the CHMP assessment report and

translation timetable.

Furthermore, the CHMP considered that teclistamab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.9. Tezspire - tezepelumab - EMEA/H/C/005588

AstraZeneca AB; add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 14.10.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tezepelumab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.10. Thalidomide Lipomed - thalidomide - EMEA/H/C/005715

Lipomed GmbH; treatment of multiple myeloma

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation

timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.11. Vabysmo - faricimab - EMEA/H/C/005642

Roche Registration GmbH; treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 14.10.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus, together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that faricimab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendations dated 11 July 2022.

The summary of opinion was circulated for information.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. nirsevimab - PRIME - EMEA/H/C/005304

Accelerated assessment

Prevention of RSV lower respiratory tract infection. Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 17.05.2022.

The Committee was reminded of the status of this application and its remaining outstanding

issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. mavacamten - EMEA/H/C/005457

treatment of symptomatic obstructive hypertrophic cardiomyopathy

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.3. dimethyl fumarate - EMEA/H/C/005963

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a 2nd list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.4. teriparatide - EMEA/H/C/004932

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021. List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.5. gozetotide - EMEA/H/C/005488

indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. plerixafor - EMEA/H/C/005943

treatment of lymphoma and multiple myeloma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483

treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 19.05.2022, 24.03.2022. List of Questions adopted on 11.11.2021.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a 3rd list of outstanding issues with a specific timetable.

The CHMP agreed on the need to consult the non-clinical working party (NcWP) and adopted a list of questions to this group.

3.2.9. efbemalenograstim alfa - EMEA/H/C/005828

Reduction in the duration of neutropenia and the incidence of febrile neutropenia.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request for an extension to the clock stop to respond to the list of outstanding issues.

3.2.10. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. teriflunomide - EMEA/H/C/005960

treatment of multiple sclerosis (MS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.12. deucravacitinib - EMEA/H/C/005755

treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic

therapy

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.13. loncastuximab tesirine - Orphan - EMEA/H/C/005685

FGK Representative Service GmbH; treatment of adult patients with relapsed or refractory large B-cell lymphoma

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. enalapril maleate ph. eur. - PUMA - EMEA/H/C/005731

treatment of heart failure in children from birth to less than 18 years.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions.

3.3.2. eculizumab - EMEA/H/C/005652

treatment of paroxysmal nocturnal haemoglobinuria

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. dabigatran etexilate - EMEA/H/C/006023

Prevention of venous thromboembolic events

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. etranacogene dezaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/004827

Accelerated assessment

CSL Behring GmbH; treatment of adults with Haemophilia B

Scope: List of questions

Action: For information

The Committee discussed the issues identified in this application.

The Committee endorsed the CHMP recommendation and scientific discussion together with the list of questions, as adopted by CAT.

3.3.5. tislelizumab - Orphan - EMEA/H/C/005919

Novartis Europharm Limited; treatment of adult patients with unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. raltegravir potassium - EMEA/H/C/005813

treatment of human immunodeficiency virus (HIV-1)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.7. tislelizumab - EMEA/H/C/005542

treatment of locally advanced or metastatic non-squamous non-small cell lung cancer in adults, treatment of locally advanced or metastatic squamous non-small cell lung cancer in adults, locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. ivosidenib - Orphan - EMEA/H/C/005936

Les Laboratoires Servier; treatment of acute myeloid leukaemia and treatment of metastatic cholangiocarcinoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. tremelimumab - Orphan - EMEA/H/C/006016

AstraZeneca AB; For use in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362

prevention of dengue disease

Scope: Update on the status of the procedure

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022, 11.11.2021. List of Questions adopted on 24.06.2021.

The CHMP noted the update on the procedure. The CHMP adopted a revised list of questions to the SAG.

The CHMP noted the timetable.

3.4.2. artesunate - Orphan - EMEA/H/C/005718

B And O Pharm; Treatment of severe malaria

Scope: Letter by the applicant dated 28.06.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.09.2021, 22.07.2021. List of Questions adopted on 22.04.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.4.3. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.4.4. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

Action: For adoption

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in January 2022.

3.4.5. bardoxolone methyl - Orphan - EMEA/H/C/005869

Reata Ireland Limited; treatment of chronic kidney disease

Scope: Letter by the applicant dated 01.07.2022 requesting an extension to the clock stop to respond to the list of questions adopted in February 2022.

Action: For adoption

List of Questions adopted on 24.02.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in February 2022.

3.4.6. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: Letter by the applicant dated 28.06.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in June 2022.

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 16.09.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in June 2022.

3.4.7. bevacizumab - EMEA/H/C/005574

treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer; first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer; first-line treatment of patients with advanced and/or metastatic renal cell cancer.

Scope: Letter by the applicant dated 27.06.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in February 2022.

Action: For adoption

List of Outstanding Issues adopted on 24.02.2022. List of Questions adopted on 22.04.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in February 2022.

3.4.8. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155

prevention of dengue disease

Scope: Update on the status of the procedure

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022, 11.11.2021. List of Questions adopted on 24.06.2021.

The CHMP noted the update on the procedure. The CHMP adopted a revised list of questions to the SAG.

The CHMP noted the timetable.

3.4.9. infigratinib - Orphan - EMEA/H/C/005361

Helsinn Birex Pharmaceuticals Limited; treatment of cholangiocarcinoma

Scope: Letter by the applicant dated 01.07.2022 requesting an extension to the clock stop to respond to the list of questions adopted in March 2022.

Action: For adoption

List of Questions adopted on 28.03.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Tuznue - trastuzumab - EMEA/H/C/005066 / Hervelous - trastuzumab - EMEA/H/C/005880

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: re-examination timetable; re-examination rapporteurs were appointed at the CHMP PROM on 11 July 2022

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion: 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

The CHMP noted the grounds for re-examination and the draft re-examination timetable.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Parsaclisib Incyte Biosciences Distribution B.V. – paraclisib – Orphan - EMEA/H/C/005893

Incyte Biosciences Distribution B.V.; treatment of relapsed or refractory marginal zone lymphoma (MZL)

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 22.04.2022.

The CHMP noted the withdrawal of the marketing authorisation application.

3.7.2. Exkivity - mobocertinib - EMEA/H/C/005621

Takeda Pharma A/S; Treatment of adult patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Scope: Withdrawal of marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 11.11.2021.

See 2.1

An oral explanation was held on 20 July 2022. The presentation by the applicant focused on the clinical data in support of the application.

The CHMP noted the withdrawal of the marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Dupixent - dupilumab - EMEA/H/C/004390/X/0057

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: For adoption

List of Questions adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.

The CHMP noted the letter of recommendation dated 17 May 2022.

4.1.2. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/X/0079/G

Gilead Sciences Ireland UC

Rapporteur: Bruno Sepodes, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension application to introduce a new strength (90 mg/90 mg/120 mg/6 mg film-coated tablets). The extension application is grouped with a type II variation (C.I.6.a) to include treatment of human immunodeficiency virus 1 (HIV 1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in paediatric patients aged from 2 years and with body weight at least 14 kg. Sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.1) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.

The CHMP noted the letter of recommendation dated 19 July 2022.

The summary of opinion was circulated for information.

4.1.3. Spikevax - elasomeran - EMEA/H/C/005791/X/0064

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop

Scope: "Extension application to add a new strength of 0.10 mg/ml in a 5-dose vial."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.

The CHMP endorsed the DHPC and communication plan.

4.1.4. Spikevax - elasomeran - EMEA/H/C/005791/X/0065

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop

Scope: "Extension application to add a new strength of 0.10 mg/ml in pre-filled syringe."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus, together with the CHMP assessment report and translation timetable.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G

Gilead Sciences Ireland UC

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 24.03.2022. List of Questions adopted on 14.10.2021.

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the 2nd list of outstanding issues and a specific timetable.

4.2.2. Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G

AstraZeneca AB

Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić

Scope: "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."

Action: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 24.02.2022.

The Committee discussed the issues identified in this application, concerning non-clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the 2nd list of outstanding issues and a specific timetable.

The CHMP agreed on the need to consult the non-clinical working party (NcWP) and adopted a list of questions to this group.

4.2.3. Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Jayne Crowe, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to:
- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use).
- add a new strength of 360 mg (150 mg/ml) for risankizumab solution for injection (in cartridge) for subcutaneous use.
The above new presentations are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. The RMP (version 4.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 22.04.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues, concerning clinical aspects.
The Committee adopted a list of outstanding issues with a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Refixia - nonacog beta pegol - EMEA/H/C/004178/X/0027/G

Novo Nordisk A/S

Rapporteur: Andrea Laslop

Scope: "Extension application to introduce a new strength (3000 IU Powder and solvent for solution for injection). The extension application is grouped with a type II variation (B.II.d.1.e).
Sections 1, 2, 5.3, 6.3, 6.6 and 8 of the SmPC, the Labelling and Package Leaflet are updated."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Tenkasi - oritavancin - EMEA/H/C/003785/X/0036

Menarini International Operations Luxembourg S.A.

Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to add a new strength of 1200 mg for powder for concentrate

for solution for infusion. The RMP (version 4) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Ultomiris - ravulizumab - EMEA/H/C/004954/X/0027/G

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with new strength (245 mg) and route of administration (subcutaneous use), grouped with a type II variation (C.I.4) to align the summary of product characteristics and labelling of Ultomiris intravenous formulation (IV) with the proposed Ultomiris subcutaneous formulation (SC).
The RMP (version 5.0) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning the wording of the indication.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Ceprotin - human protein c - EMEA/H/C/000334/II/0127

Takeda Manufacturing Austria AG

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include long-term prophylaxis (deletion of wording 'short-term' and currently listed conditions) of purpura fulminans and coumarin induced skin necrosis in patients with severe congenital protein C deficiency, based on a re-analysis of long-term prophylaxis data from the pivotal study 400101; a phase 2/3 clinical study undertaken to evaluate PK, safety and efficacy of Ceprotin in patients with severe congenital PC deficiency for the treatment of acute thrombotic episodes, for short-term thromboembolic prophylaxis and for long-term prophylactic treatment. As a consequence, sections 4.1, 4.2 and 4.4 of the SmPC are updated and the Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 2.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to correct the address of the manufacturer of the biological active substance in Annex II following variation EMEA/H/C/000334/IAIN/0126/G."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.2. Dupixent - dupilumab - EMEA/H/C/004390/II/0062

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy, based on the pivotal study R668-EE-1774. This is an ongoing phase 3, randomized, double-blind, placebo-controlled, 3-part (A, B, C) safety and efficacy study with an initial 24-week treatment period in adults (≥18 years of age) and adolescents (≥12 to <18 years of age) with EoE, and which includes an extended treatment period to a total of 52 weeks. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Dupixent - dupilumab - EMEA/H/C/004390/II/0063

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy, based on results from studies EFC16459 and EFC16460 (PRIME and PRIME2); these are two phase 3, 24-week, randomized, double-blind, placebo-controlled, multi-centre, parallel group studies undertaken to evaluate the efficacy and safety of dupilumab in patients 18 years of age and older with moderate to severe PN, who are inadequately controlled on topical prescription therapies or when those therapies are not advisable. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. As part of this application, the MAH is also requesting a 1-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. Evrysdi - risdiplam - Orphan - EMEA/H/C/005145/II/0005/G

Roche Registration GmbH

Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Jan Neuhauser

Scope: "Grouping of three variations as follows:
Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application.
Type IAIN, B.IV.1.a.1 variation to update Evrysdi pack configuration with the addition of a new 1 mL oral syringe into the product carton allowing precise dosing of infants below 2 months of age. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance.

Type IAIN, B.IV.1.b variation to remove the spare unit of 12 mL oral syringe out of the two units currently provided in the product carton. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee discussed the issues identified in this application concerning quality and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.5. Imcivree - setmelanotide - Orphan - EMEA/H/C/005089/II/0002/G

Rhythm Pharmaceuticals Netherlands B.V.

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Anna Mareková

Scope: "Group of variations consisting of:
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted.
C.I.6.a - To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Alström syndrome (AS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.

The CHMP noted that the applicant withdrew the application for the use of Imcivree to treat obesity and control hunger associated with genetically confirmed Alström syndrome.

The Committee confirmed that all issues previously identified in the remaining application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion as well as the question-and-answer document on the withdrawal were circulated for information.

5.1.6. Imfinzi - durvalumab - EMEA/H/C/004771/II/0045

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC), based on final results from study D419CC00002 (HIMALAYA); This was a randomized, open-label, multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma. As a consequence, sections 4.1, 4.2, 4.4, 4.8,

5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet. Version 6.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Imfinzi - durvalumab - EMEA/H/C/004771/II/0046

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi in combination with chemotherapy for the treatment of adults with locally advanced or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi-regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the package leaflet has been updated accordingly. Version 7.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application concerning clinical aspects and the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. Imvanex - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0076

Bavarian Nordic A/S

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include active immunisation against monkeypox and disease caused by vaccinia virus in adults for Imvanex; as a consequence, sections 1, 4.1, 4.2, 4.4, 4.6 and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.2."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion as well as the EMA news announcement were circulated for

information.

5.1.9. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with stage IB (T2a ⩾ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicenter study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.10. Libtayo - cemiplimab - EMEA/H/C/004844/II/0028

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include Libtayo in combination with platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations; as a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.11. Lynparza - olaparib - EMEA/H/C/003726/II/0053

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone, based on the results of the pivotal Phase III study PROpel (D081SC00001) and supportive evidence from study 8 (D081DC00008). PROpel is a Phase

III, randomised, double-blind, placebo-controlled, multicentre study evaluating olaparib vs placebo in combination with abiraterone as first-line treatment for men with mCRPC. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC for Lynparza tablets are being updated. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated accordingly. The RMP version 24 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial and linguistic changes in the SmPC and Package Leaflet.
As part of the application, the MAH is also requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.13. Olumiant - baricitinib - EMEA/H/C/004085/II/0028

Eli Lilly Nederland B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski

Scope: "C.I.6 - Extension of indication to include treatment of coronavirus disease 2019 (COVID 19) in hospitalised adult and paediatric patients aged 10 years and older who require low-flow oxygen or non-invasive ventilation/high flow oxygen for Olumiant; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated.

The Annex II and the Package Leaflet are updated in accordance. Version 11.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 14.10.2021, 22.07.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.14. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0014/G

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include first-line treatment of advanced RET-mutant medullary thyroid cancer (MTC) in adults and adolescents 12 years and older based on interim results from study LIBRETTO-001 (LOXO-RET-17001) on the clinical safety and efficacy of selpercatinib in patients with RET-mutant MTC who are cabozantinib and vandetanib treatment-naïve (MTC:-Cab/-Van). LIBRETTO-001 is a global, multicohort, open-label, Phase 1/2 study in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted.
As part of the application the MAH is requesting a 1-year extension of the market protection. The application also includes an updated Phase II Environmental Risk Assessment in order to reflect the patient population as per the approved indication.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The CHMP noted the letter of recommendations dated 20 July 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.15. Tecartus - brexucabtagene autoleucel - Orphan - ATMP - EMEA/H/C/005102/II/0008/G

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Group of variations including an extension of indication to include treatment of adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (B-ALL)

for Tecartus and a type IB variation to change the Drug Product Dose specification for the new indication. As a consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template.
B.II.d.1.z (Type IB).", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 18.03.2022, 10.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the CAT opinion, the CHMP adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.16. Trecondi - treosulfan - Orphan - EMEA/H/C/004751/II/0014

medac Gesellschaft fur klinische Spezialpraparate mbH

Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos

Scope: "Extension of indication to include additional non-malignant transplant indications (non-malignant diseases in the paediatric population) for Trecondi 1 g/5 g powder for solution for infusion based on final 12-months follow-up results of study MC-FludT.16/NM; a randomised phase II interventional study aimed to compare Treosulfan-based conditioning therapy with Busulfan-based conditioning prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with non-malignant diseases.
Further, the MAH proposes to amend an existing warning on skin toxicity based on new literature data. Moreover, the MAH proposes to introduce a slightly modified dosing regimen according to the patient's body surface based on long-term follow-up data of paediatric study MC-FludT.17/M, a Phase II trial to describe the safety and efficacy of Treosulfan based conditioning therapy prior to allogeneic haematopoietic stem cell transplantation in paediatric patients with haematological malignancies, as well as a final analysis of the population pharmacokinetics of treosulfan in paediatric patients. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. Ultomiris - ravulizumab - EMEA/H/C/004954/II/0026

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adult patients with generalised myasthenia gravis (gMG). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPC and package leaflet. The Applicant also requested 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.1.18. Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance, based on final results from 1 Phase II study (V114-008) and 7 Phase III studies (V114-023, V114-024, V114-025, V114-027, V114-029, V114-030, V114-031); these are interventional studies to evaluate the safety, tolerability and immunogenicity of V114 in healthy and immunocompromised infants, children and adolescents. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include editorial changes in the product information. Version 1.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.19. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 13.05.2022, 18.02.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.20. WS2150
DuoPlavin - clopidogrel / acetylsalicylic acid - EMEA/H/C/001143/WS2150/0060
Iscover - clopidogrel - EMEA/H/C/000175/WS2150/0146
Plavix - clopidogrel - EMEA/H/C/000174/WS2150/0145

sanofi-aventis groupe

Lead Rapporteur: Bruno Sepodes, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include clopidogrel in combination with acetylsalicylic acid in ST segment elevation acute myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI); as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. Version 1.5 of the RMP has also been submitted. In addition, an editorial update has been made to the labelling."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee discussed the issues identified in this application, concerning non-clinical and clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

No items

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. leniolisib - Orphan - H0005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 4 recommendations for eligibility to PRIME: 1 was accepted and 3 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0011/G

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege

Scope: "Grouped variation:
- C.I.4 (Type II): Update of section 5.1 of the SmPC in order to introduce data on clinical efficacy against the Omicron variant of concern, based on data from study 2019nCoV-101 (Parts 1 and 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and published literature. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information.
- C.I.13 (Type II): Submission of the final clinical report from study 2019nCoV-101 (Part 1), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and

Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988).
This submission addresses the post-authorisation measures MEA 009, REC 041 and REC 042."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.2. Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a 0.5 mL third dose for Nuvaxovid, to boost subjects that have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an authorised mRNA or adenoviral vector vaccine (heterologous booster dose), based on interim data from study 2019nCoV-101 (Part 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), final data from study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and data from the COV-BOOST study (Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial); the Package Leaflet is updated accordingly. The RMP version 1.2 has also been submitted. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.3. Spikevax - elasomeran - EMEA/H/C/005791/II/0057

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly."

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

9.1.4. Spikevax - elasomeran - EMEA/H/C/005791/II/0066

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus

Scope: "Update of sections 4.5 and 5.1 of the SmPC in order to introduce new clinical data regarding the co-administration of Spikevax with a high-dose quadrivalent influenza vaccine (QIV-HD), based on final results from study QHD00028 (NCT04969276), a Phase II, Open-label Study to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'."

Action: For adoption

The Committee discussed the issues identified in this application, regarding clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.5. Veklury - remdesivir - EMEA/H/C/005622/II/0034/G

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Grouping variation to update section 5.1 of the SmPC in relation to information regarding the antiviral activity of Veklury. This submission of the final results of study ACTT-1 with the final sequencing and phenotyping analysis and the full virology report including activity against variants is related to the Specific Obligation 012. Furthermore, Annex II is updated accordingly to reflect the fulfilment of the specific obligations following this submission. Finally, the MAH provided data on the alternative method (i.e., the SARS-CoV-2 replicon system) that can be utilised to allow further testing of the Nsp12 mutation A547V as requested in REC 027 that is also considered fulfilled. The Package Leaflet and the RMP (version 4.0) are updated accordingly.
Furthermore, the CHMP is of the opinion that in light of all the data generated throughout all the specific obligations providing a comprehensive dataset, the benefit-risk balance of the above-mentioned medicinal product remains favourable and also considering the evidence of compliance with all specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article 14(1) of Regulation No 726/2004."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

9.1.6. Darunavir Krka d.d. – darunavir – EMEA/H/C/004891

KRKA d.d. Novo mesto; treatment of HIV-1 infection

Rapporteur: John Joseph Borg

Scope: Withdrawal of marketing authorisation

Action: For information

CHMP noted the withdrawal of the marketing authorisation.

9.1.7. Visudyne - verteporfin – EMEA/H/C/000305

CHEPLAPHARM Arzneimittel GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Kirstine Moll Harboe

Scope: Adoption of a DHPC

Action: For adoption

CHMP adopted the DHPC.

9.1.8. Crysvita - burosumab – Orphan - EMEA/H/C/004275/II/0028

Kyowa Kirin Holdings B.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of the adverse drug reactions, to split immunogenicity data into paediatric and adult populations and to update clinical efficacy in paediatric patients, upon request by the CHMP following the assessment of PAM procedures P46/006 and P46/007 and type II variations II/04 and II/10/G, based on the final results from studies UX023-CL201, UX023-CL205 and UX023-CL301. As a consequence, the last remaining specific obligation, the provision of the final CSR for study UX023-CL205, was deleted from the Annex II. This was an open-label, phase 2 study undertaken to assess the safety, pharmacodynamics, and efficacy of KRN23 in paediatric patients between 1 and 4 years old with X-linked Hypophosphataemia (XLH). With the fulfilment of this specific obligation the MAH is requesting for the Crysvita MA to no longer be subject to specific obligations. The Package Leaflet was updated accordingly. The RMP version 5.0 was agreed during the procedure."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

9.1.9. JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0053/G

Janssen-Cilag International N.V.

Rapporteur: Christophe Focke

Scope: "Update of section 4.2 of the SmPC to introduce a heterologous booster dose of JCOVDEN following priming with another adenoviral vector-based vaccine and an inactivated whole virion COVID-19 vaccine based on literature evidence from studies COV-BOOST and RHH-01 respectively. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as homologous and heterologous booster dose based on data from studies COV2008, a randomised, double-blind Phase 2 study and literature evidence from studies COV-BOOST, RHH-001 and DMID 21-0012. The Package Leaflet is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, regarding clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.10. Rubraca - rucaparib - EMEA/H/C/004272/II/0029

Clovis Oncology Ireland Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022, 11.11.2021.

The Committee discussed the issues identified in this application, regarding clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

9.1.11. NeuroBloc – botulinum toxin type B – EMEA/H/C/000301

Sloan Pharma S.a.r.l; treatment of cervical dystonia

Rapporteur: Bruno Sepodes, Co-Rapporteur: Jayne Crowe

Scope: Withdrawal of marketing authorisation

Action: For information

CHMP noted the withdrawal of the marketing authorisation.

9.1.12. Zejula - niraparib – Orphan - EMEA/H/C/004249/II/0033

GlaxoSmithKline (Ireland) Limited

Rapporteur: Ingrid Wang, PRAC Rapporteur: Jan Neuhauser

Scope: Letter by the applicant requesting an extension to the clock stop to respond to the request for supplementary information adopted in May 2022.

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022, 10.02.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the request for supplementary information adopted in May 2022.

9.1.13. Senstend – lidocaine/ prilocaine – EMEA/H/C/005298

Plethora Pharma Solutions; treatment of primary premature ejaculation

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Withdrawal of marketing authorisation

Action: For information

CHMP noted the withdrawal of the marketing authorisation.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

10.1.1. Rubraca - rucaparib - EMEA/H/A-20/1518/C/4272/0033

Clovis Oncology Ireland Limited

Referral Rapporteur: Blanca Garcia-Ochoa, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004 based on pharmacovigilance data - opinion

Action: For adoption

The CHMP adopted an opinion by consensus, recommending that Rubraca should no longer

be used in monotherapy treatment for adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum-based chemotherapy, and who are unable to tolerate further platinum-based chemotherapy.

The CHMP agreed on the wording of a direct healthcare professional communication (DHPC) together with a communication plan.

The CHMP noted the EMA public health communication.

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Synchron Research Services – various – EMEA/H/A-31/1515

Various

Referral Rapporteur: Kristina Dunder, Referral Co-Rapporteur: Janet Koenig

Scope: Re-examination timetable

Action: For adoption

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency (Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India.

The CHMP adopted the re-examination timetable.

Re-examination - receipt of detailed grounds from MAH: 18 July 2022

Re-examination - Start of re-examination procedure: 19 July 2022

Re-examination - Rapporteur/co-rapporteur assessment report(s) circulated to CHMP:18 August 2022

Re-examination – Comments: 29 August 2022

Re-examination - Joint updated assessment report circulated to CHMP: 02 September 2022

Re-examination - Oral explanation/CHMP final opinion: September, 2022 CHMP

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

July 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. CHMP membership

End of membership

Action: For information

The CHMP thanked Jan Sjöberg and Peter Kiely for their contribution as alternates for Iceland and Ireland.

14.1.2. Vote by proxy

Bulgaria gave a PROXY to Bruno Sepodes for the entire meeting.

14.1.3. Nomination of Co-opted Member

Nomination of CHMP co-opted member in light of the expiry of mandate of co-opted member Sol Ruiz in July 2022.

Agreed areas of expertise: quality and safety (biological), with expertise in advanced therapies (gene, cell and tissue therapies)

Nomination(s) received

Action: For election

The CHMP re-elected Sol Ruiz as co-opted member in area of expertise quality and safety (biological), with expertise in advanced therapies (gene, cell and tissue therapies).

14.1.4. Timetable for August 2022 Written Procedure

Action: For adoption

The CHMP adopted the timetable for the August written procedure.

14.1.5. CHMP Co-rapporteur critique

Experience of the implementation of Co-Rapp Critique in initial marketing authorisation applications.

Action: For discussion

The CHMP noted the experience of the implementation of Co-Rapp Critique in initial marketing authorisation applications.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for July 2022

Action: For adoption

The CHMP adopted the EURD list.

Summary of recommendations and advice of PRAC meeting held on 04 July - 07 July 2022

Action: For information

The CHMP noted the information.

The members were informed about the PRAC Art 31 PhV Referral on nomegestrol/chlormadinone.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at July 2022 PDCO

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/ Sean Barry

Reports from BWP July 2022 meeting to CHMP for adoption:

- 16 reports on products in scientific advice and protocol assistance
- 18 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 28-29 June 2022.

Action: For adoption

The CHMP adopted the table of decisions.

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 04-07 July 2022. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Vice-Chair election of the Oncology Working Party (ONCWP)

Election of vice-chair of the Oncology Working Party.

Nomination(s) received

Action: For election

The CHMP elected Olli Tenhunen as vice-chair of the Oncology Working Party.

14.3.5. Vice-Chair election of the Rheumatology and Immunology Working Party (RIWP)

Election of vice-chair of the Rheumatology and Immunology Working Party.

Nomination(s) received

Action: For election

The CHMP elected Caroline Auriche as vice-chair of the Rheumatology and Immunology Working Party.

14.3.6. EC Request for a scientific opinion on the classification as medicinal products of certain substances used in blood bags CDP (citrate, dextrose and phosphate) and CDPA (citrate, dextrose, phosphate and adenine)

Follow-up on discussions at the July PROM regarding the European Commission request.

Call for a CHMP sponsor/rapporteur to prepare a response letter to the EC.

Action: For information

The CHMP noted the call for a CHMP sponsor/rapporteur and the proposed timetable.

14.3.7. Biosimilar Working Party (BSWP) - Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU

The CHMP approved the 'biosimilars approved in the EU are interchangeable' statement last May for publication in EMA webpage. However, it was recommended that a rationale document is drafted to publish alongside the statement.

Action: For adoption

The CHMP agreed on the interchangeability statement and accompanying rationale document.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

14.6.1. Outcome of CHMP Pilot on early dialogue with patient organisations

Presentation of the results of the pilot (Jan 2021 – May 2022) which reached out to patient organisations for their insights at the beginning of new orphan MAAs. Results from questionnaires completed by Co-/Rapporteurs to be discussed and way forward decided.

Action: For discussion

CHMP noted the outcome of CHMP Pilot on early dialogue with patient organisations and proposed that this should continue as an established procedure, with the inclusion of 'new' indications, in addition to orphan MAA's. The CHMP noted that the outcome report will be published.

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the information.

15.1.2. COVID-19 vaccine – EMEA/H/C/006058

immunisation to prevent COVID-19 caused by SARS-CoV-2

Scope: Rolling review

Action: For adoption

The CHMP adopted the rolling review.

List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 18-21 July 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Aaron Sosa Mejia	Alternate	Denmark	No participation in final deliberations and voting on:	Refixia - nonacog beta pegol - EMEA/H/C/004178/X/0027/G
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on:	COVID-19 vaccines
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No participation in final deliberations and voting on:	Darunavir Krka d.d. – darunavir – EMEA/H/C/004891

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Vincent Gazin	Expert	France	No interests declared	
Mona Kassem-Youssef	Expert	France	No interests declared	
Brenda Holingue	Expert	France	No interests declared	
Sargi Caizergues Lama	Expert	France	No interests declared	
Celine Jumeau	Expert	France	No interests declared	
Inne Crèvecoeur	Expert	Belgium	No participation in discussion, final deliberations and voting on:	Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001
Stefan Bonné	Expert	Belgium	No interests declared	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Fabien Carré	Expert	France	No participation in discussion, final deliberations and voting on:	Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/X/0079/G Veklury - remdesivir - EMEA/H/C/005622/II/0034/G
Mario Miguel Coelho da Silva Rosa	Expert	Portugal	No interests declared	
Caroline Auriche-Benichou	Expert	France	No interests declared	
Eeva Sofia Leinonen	Expert	Finland	No interests declared	
Benita Cullen	Expert	Ireland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Iftekhar Khan	Expert	Ireland	No interests declared	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final deliberations and voting on:	Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G
Mas Parra Paloma	Expert	Spain	No restrictions applicable to this meeting	
Alicia Pérez González	Expert	Spain	No interests declared	
Consuelo Mejías Pavón	Expert	Spain	No interests declared	
Poleta Luga	Expert	Germany	No interests declared	
Lars Krueger	Expert	Germany	No restrictions applicable to this meeting	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Ulrike Wermes	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Katharina Hees	Expert	Germany	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Claudia Reichmann	Expert	Germany	No interests declared	
Attila Sebe	Expert	Germany	No interests declared	
Jens Peter Hartmann	Expert	Germany	No interests declared	
Robert Pollmann	Expert	Germany	No interests declared	
Sanna Gevers	Expert	Netherlands	No interests declared	
Stavros Nikolakopoulos	Expert	Netherlands	No interests declared	
Hester Peltenburg	Expert	Netherlands	No interests declared	
Eleonora Wijnans	Expert	Netherlands	No interests declared	
Ineke Havinga	Expert	Netherlands	No interests declared	
Johannes Petrus Theodorus Span	Expert	Netherlands	No interests declared	
Nienke Rodenhuis	Expert	Netherlands	No interests declared	
Patrick Vrijlandt	Expert	Netherlands	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
George Aislaitner	Expert	Germany	No interests declared	
Elly Vereyken	Expert	Netherlands	No restrictions applicable to this meeting	
Lourdes Fernandez Martn	Expert	Spain	No restrictions applicable to this meeting	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Susanne Hopner Rasmussen	Expert	Denmark	No interests declared	
Torsten Holm Nielsen	Expert	Denmark	No restrictions applicable to this meeting	
Nanna Borup Johansen	Expert	Denmark	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Serena Zamponi	Expert	Italy	No participation in discussion, final deliberations and voting on:	Exkivity - mobocertinib - EMEA/H/C/005621 dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362 dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155 Ceprotin - human protein c - EMEA/H/C/000334/II/0127
Cristina Migali	Expert	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert	Italy	No interests declared	
Angelo Molinaro	Expert	Italy	No interests declared	
Antonella Isgrò	Expert	Italy	No interests declared	
Gabriella Passacquale	Expert	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brigitte Mueller	Expert	Austria	No interests declared	
Ilona G Reischl	Expert	Austria	No interests declared	
Harald Bernsteiner	Expert	Austria	No interests declared	
Christine Vaculik	Expert	Austria	No interests declared	
Jakob Paur	Expert	Austria	No restrictions applicable to this meeting	
Elisabeth Wischnitzki	Expert	Austria	No interests declared	
Hannah Münch	Expert	Austria	No interests declared	
Susanne Wolf	Expert	Austria	No interests declared	
Peter Mol	Expert	Netherlands	No interests declared	
Marion Haberkamp	Expert	Germany	No interests declared	
Quirine Fillekes	Expert	Netherlands	No interests declared	
Jeroen Koomen	Expert	Netherlands	No interests declared	
Louise Claessen	Expert	Netherlands	No interests declared	
Andreas Kirisits	Expert	Austria	No interests declared	
Heide Muckenfuß	Expert	Germany	No interests declared	
Alexandra Branchu	Expert	Luxembourg	No part in discussions, final deliberations and voting on:	Dupixent - dupilumab - EMEA/H/C/004390/X/0057 Dupixent - dupilumab - EMEA/H/C/004390/II/0062 Dupixent - dupilumab - EMEA/H/C/004390/II/0063 WS2150 - DuoPlavin / Iscover / Plavix
Valeria Zoccano	Expert	Italy	No interests declared	
Wendy van Loon	Expert	Netherlands	No restrictions applicable to this meeting	
Martina Schuessler-Lenz	Expert	Germany	No interests declared	
Lothar Bergmann	Expert	Germany	No restrictions applicable to this meeting	
Petra Prouzova	Expert	Czechia	No interests declared	
Sara Galluzzo	Expert	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Galluzzo	Expert	Greece	No interests declared	
Olli Tenhunen	Expert	Fina	No interests declared	
Finnuala Lonsdale	Expert	Ireland	No participation in discussion, final deliberations and voting on:	Tezspire - tezepelumab - EMEA/H/C/005588 nirsevimab - EMEA/H/C/005304 tremelimumab EMEA/H/C/006016 Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G Imfinzi - durvalumab - EMEA/H/C/004771/II/0045 Imfinzi - durvalumab - EMEA/H/C/004771/II/0046 Lynparza - olaparib - EMEA/H/C/003726/II/0053
Sabine Mayrhofer	Expert	Germany	No interests declared	
Filip Kukulski	Expert	Health Canada	No interests declared	
Mohit Khera	Expert	TGA Australia	No interests declared	
Megan Hickie	Expert	TGA Australia	No interests declared	
Evelyn Soo	Expert	Health Canada	No interests declared	
Meeting run with support from relevant EMA staff.				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

27 September 2022
EMA/CHMP/652591/2022

Annex to 18-21 July 2022 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for July 2022: **For adoption**	Adopted

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for July 2022: **For adoption**	Adopted

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Chenodeoxycholic acid Leadiant - chenodeoxycholic acid - EMEA/H/C/004061/S/0020, Orphan Leadiant GmbH, Rapporteur: Anastasia Mountaki, PRAC Rapporteur: Adam Przybylkowski	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
DECTOVA - zanamivir - EMEA/H/C/004102/S/0013 GlaxoSmithKline Trading Services Limited, Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
Elaprase - idursulfase - EMEA/H/C/000700/S/0099 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Evoltra - clofarabine - EMEA/H/C/000613/S/0076	Positive Opinion adopted by consensus together with the CHMP assessment report and

Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant	translation timetable. The Marketing Authorisation remains under exceptional circumstances.
Firdapse - amifampridine - EMEA/H/C/001032/S/0073 SERB SA, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The Marketing Authorisation remains under exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

ADYNOVI - rurioctocog alfa pegol - EMEA/H/C/004195/R/0033 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Alkindi - hydrocortisone - EMEA/H/C/004416/R/0014 Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Fasenra - benralizumab - EMEA/H/C/004433/R/0044 AstraZeneca AB, Rapporteur: Fátima Ventura, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: David Olsen	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Hemlibra - emicizumab - EMEA/H/C/004406/R/0032 Roche Registration GmbH, Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Intrarosa - prasterone - EMEA/H/C/004138/R/0022 Endoceutics S.A., Rapporteur: Jean-Michel Race, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur:	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Menno van der Elst	Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Jorveza - budesonide - EMEA/H/C/004655/R/0016, Orphan Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, Co-Rapporteur: Tomas Radimersky, PRAC Rapporteur: Zane Neikena	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Miglustat Gen.Orph - miglustat - EMEA/H/C/004366/R/0022 Gen.Orph, Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 23.06.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
MVASI - bevacizumab - EMEA/H/C/004728/R/0025 Amgen Technology (Ireland) Unlimited Company, Duplicate, Duplicate of KYOMARC, Rapporteur: Eva Skovlund, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Nyxoid - naloxone - EMEA/H/C/004325/R/0014 Mundipharma Corporation (Ireland) Limited, Rapporteur: Bruno Sepodes, Co-Rapporteur: Elita Poplavska, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Ocrevus - ocrelizumab - EMEA/H/C/004043/R/0033 Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Brigitte Keller-Stanislawski	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
Ozempic - semaglutide - EMEA/H/C/004174/R/0030 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Mari Thorn	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that

	the renewal of the marketing authorisation can be granted with unlimited validity.
TOOKAD - padeliporfin - EMEA/H/C/004182/R/0019 STEBA Biotech S.A, Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Maia Uusküla Request for Supplementary Information adopted on 23.06.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.
VeraSeal - human fibrinogen / human thrombin - EMEA/H/C/004446/R/0018 Instituto Grifols, S.A., Rapporteur: Andrea Laslop, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Amelia Cupelli Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

GAVRETO - pralsetinib - EMEA/H/C/005413/R/0006 Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
NINLARO - ixazomib - EMEA/H/C/003844/R/0040, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.
RYBREVANT - amivantamab - EMEA/H/C/005454/R/0002 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Brigitte Keller-Stanislawski	Positive Opinion adopted by consensus together with the CHMP assessment report. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its July 2022 meeting:	
EMEA/H/C/PSUSA/00001255/202111 (erlotinib) CAPS: **Tarceva** (EMEA/H/C/000618) (erlotinib), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia NAPS: **NAPs** - EU PRAC Rapporteur: Marie Louise Schougaard Christiansen, "18/11/2019 To: 17/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the adverse reactions hepatitis and acute hepatitis and update of section 4.4 of the SmPC to amend a warning/precaution regarding hepatotoxicity. The Package leaflet is updated accordingly. Update of section 4.8 to add the adverse reaction pneumatosis with a frequency rare. No updates to the package leaflet are warranted since symptoms of pneumatosis intestinalis are already listed.
EMEA/H/C/PSUSA/00002798/202111 (sufentanil) CAPS: **Dzuveo** (EMEA/H/C/004335) (sufentanil), Laboratoire Aguettant, Rapporteur: Hrefna Gudmundsdottir **Zalviso** (EMEA/H/C/002784) (sufentanil), FGK Representative Service GmbH, Rapporteur: Daniela Philadelphy NAPS: **NAP** - EU PRAC Rapporteur: Adam Przybylkowski, "30/11/2018 To: 30/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.4. of the SmPC to add a warning/precaution regarding opioid induced hyperalgesia and section 2 of the Package Leaflet accordingly.
EMEA/H/C/PSUSA/00010180/202111 (cabozantinib) CAPS: **CABOMETYX** (EMEA/H/C/004163) (cabozantinib), Ipsen Pharma, Rapporteur: Ingrid Wang **Cometriq** (EMEA/H/C/002640) (cabozantinib), Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add

Elst, "28/11/2018 To: 28/11/2021"	cutaneous vasculitis and pneumothorax as adverse reactions under SOC Skin and subcutaneous tissue disorders with a frequency not known and SOC Respiratory, thoracic and mediastinal disorders with frequency uncommon, respectively. The Package leaflet is updated accordingly. In addition, only for Cabometix medicinal product containing cabozantinib: update of section 4.4 of the SmPC to update the warning on hypertension.
EMEA/H/C/PSUSA/00010472/202111 (osimertinib) CAPS: **TAGRISSO** (EMEA/H/C/004124) (osimertinib), AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Menno van der Elst, "13/11/2019 To: 12/11/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.2, 4.4 and 4.8 of the SmPC to amend the table regarding dose modifications to recommend permanently discontinuation in case of adverse reactions Stevens-Johnson Syndrome and Aplastic anaemia, to add a warning on Aplastic anaemia, to add the adverse reaction Aplastic Anaemia with frequency rare and amend the description for haematologic events, to add the adverse reaction Left ventricular ejection fraction decreased with frequency common and Cardiac failure with frequency uncommon. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010552/202112 (edotreotide) CAPS: **SomaKit TOC** (EMEA/H/C/004140) (edotreotide), Advanced Accelerator Applications, Rapporteur: Maria Concepcion Prieto Yerro NAPS: **NAPs** - EU PRAC Rapporteur: Ronan Grimes, "08/12/2020 To: 07/12/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.4 of the SmPC to amend a warning on errors of interpretation of gallium (68Ga) edotreotide images. The Package leaflet is updated accordingly. Update of section 4.8 of the SmPC to add a description of cases in which physiological uptake of gallium (68Ga) edotreotide by splenic

	tissue has been misdiagnosed as neuroendocrine tumour, leading to unnecessary intervention. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010643/202112 (lutetium (177Lu) oxodotreotide) CAPS: **LUTATHERA** (EMEA/H/C/004123) (lutetium (177Lu) oxodotreotide), Advanced Accelerator Applications, Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski, "20/12/2020 To: 19/12/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add a warning/precaution regarding cases of hypersensitivity reactions and stopping the treatment immediately if the hypersensitivity reaction occurs; and the adverse reaction angioedema with a frequency not known; The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010897/202112 (elasomeran) CAPS: **Spikevax** (EMEA/H/C/005791) (elasomeran), Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "30/06/2021 To: 30/12/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following changes: Update of section 4.8 of the SmPC to add the adverse reaction "extensive swelling of vaccinated limb" with a frequency "not known". The package leaflet is updated accordingly. Furthermore, the MAH took the opportunity to update Annex II with regards to PSUR requirements.
EMEA/H/C/PSUSA/00010912/202112 (COVID-19 Vaccine (ChAdOx1-S [recombinant]) (Vaxzevria)) CAPS: **Vaxzevria** (EMEA/H/C/005675) (COVID 19 Vaccine (ChAdOx1 S [recombinant])), AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "29/06/2021 To: 28/12/2021"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add tinnitus, paraesthesia and hypoaesthesia with frequency 'uncommon' based on data assessed within this procedure. The Package leaflet is updated accordingly.
EMEA/H/C/PSUSA/00010955/202112 (roxadustat)	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the

CAPS: **Evrenzo** (EMEA/H/C/004871) (roxadustat), Astellas Pharma Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anna Mareková, "17/06/2021 To: 16/12/2021"	PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product, concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reactions Secondary hypothyroidism and Blood thyroid stimulating hormone decreased with a frequency unknown and a warning/precaution regarding these adverse reactions. The Package leaflet is updated accordingly.

B.4. EPARs / WPARs

COVID-19 Vaccine (inactivated, adjuvanted) Valneva - SARS-CoV-2 virus, strain wuhan hCoV-19/Italy/INMI1-isl/2020, inactivated - EMEA/H/C/006019 Valneva Austria GmbH, indicated for active immunisation against coronavirus disease 2019 (COVID-19), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Parsaclisib Incyte Biosciences Distribution B.V. (WD) - parsaclisib - EMEA/H/C/005893, Orphan Incyte Biosciences Distribution B.V., treatment of relapsed or refractory marginal zone lymphoma (MZL), New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Pepaxti - melphalan flufenamide - EMEA/H/C/005681 Oncopeptides AB, treatment of multiple myeloma, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Ranivisio - ranibizumab - EMEA/H/C/005019 Midas Pharma GmbH, The treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to choroidal neovascularisation (CNV), Similar biological application (Article 10(4) of Directive No	For information only. Comments can be sent to the PL in case necessary.

2001/83/EC)	
RAYVOW - lasmiditan - EMEA/H/C/005332 Eli Lilly Nederland B.V., acute treatment of migraine with or without aura in adults, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
ROCTAVIAN - valoctocogene roxaparvovec - EMEA/H/C/005830, Orphan, ATMP BioMarin International Limited, treatment of severe haemophilia A, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Scemblix - asciminib - EMEA/H/C/005605, Orphan Novartis Europharm Limited, treatment of Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sunlenca - lenacapavir - EMEA/H/C/005638 Gilead Sciences Ireland Unlimited Company, treatment of human immunodeficiency virus type 1 (HIV-1) infection, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
VEGZELMA - bevacizumab - EMEA/H/C/005534 Celltrion Healthcare Hungary Kft., Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer. First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer. First-line treatment of patients with advanced and/or metastatic renal cell cancer., Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Benepali - etanercept - EMEA/H/C/004007/II/0065/G	Request for supplementary information adopted with a specific timetable.

Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 14.07.2022.	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0134/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0135/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0136 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Dupixent - dupilumab - EMEA/H/C/004390/II/0059/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 30.06.2022. Request for Supplementary Information adopted on 07.04.2022.	Positive Opinion adopted by consensus on 30.06.2022.
Edarbi - azilsartan medoxomil - EMEA/H/C/002293/II/0031 Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
Elaprase - idursulfase - EMEA/H/C/000700/II/0095 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 07.07.2022, 24.03.2022.	Request for supplementary information adopted with a specific timetable.
Elaprase - idursulfase - EMEA/H/C/000700/II/0098/G Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 10.06.2022, 07.04.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Entyvio - vedolizumab -	Request for supplementary information adopted

EMEA/H/C/002782/II/0070/G Takeda Pharma A/S, Rapporteur: Armando Genazzani Request for Supplementary Information adopted on 21.07.2022.	with a specific timetable.
Erelzi - etanercept - EMEA/H/C/004192/II/0040/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Erelzi - etanercept - EMEA/H/C/004192/II/0042/G Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0022/G Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0002/G AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Firazyr - icatibant - EMEA/H/C/000899/II/0054/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0027 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/002617/II/0117 AstraZeneca AB, Rapporteur: Christophe Focke Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0154/G Merck Europe B.V., Rapporteur: Johann	Request for supplementary information adopted with a specific timetable.

Lodewijk Hillege Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.	
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/II/0075/G Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Increlex - mecasermin - EMEA/H/C/000704/II/0076 Ipsen Pharma, Rapporteur: Outi Mäki-Ikola Opinion adopted on 30.06.2022. Request for Supplementary Information adopted on 28.04.2022.	Positive Opinion adopted by consensus on 30.06.2022.
Increlex - mecasermin - EMEA/H/C/000704/II/0077/G Ipsen Pharma, Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0023 Bayer AG, Rapporteur: Thalia Marie Estrup Blicher Opinion adopted on 30.06.2022. Request for Supplementary Information adopted on 07.04.2022.	Positive Opinion adopted by consensus on 30.06.2022.
Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0066/G Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Lynparza - olaparib - EMEA/H/C/003726/II/0055/G AstraZeneca AB, Rapporteur: Alexandre Moreau Opinion adopted on 30.06.2022. Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus on 30.06.2022.
Mekinist - trametinib - EMEA/H/C/002643/II/0053/G Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik Opinion adopted on 14.07.2022. Request for Supplementary Information adopted on 22.04.2022.	Positive Opinion adopted by consensus on 14.07.2022.

Mosquirix - plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted) - EMEA/H/W/002300/II/0061/G GlaxoSmithkline Biologicals SA, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0033/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 17.03.2022, 02.12.2021.	Positive Opinion adopted by consensus on 21.07.2022.
Ngenla - somatrogon - EMEA/H/C/005633/II/0001/G, Orphan Pfizer Europe MA EEIG, Rapporteur: Jayne Crowe Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 19.05.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Nuceiva - botulinum toxin type A - EMEA/H/C/004587/II/0025/G Evolus Pharma B.V., Rapporteur: Jayne Crowe Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
OXERVATE - cenegermin - EMEA/H/C/004209/II/0038/G, Orphan Dompe farmaceutici S.p.A., Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Padcev - enfortumab vedotin - EMEA/H/C/005392/II/0001 Astellas Pharma Europe B.V., Rapporteur: Aaron Sosa Mejia Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/II/0020 Accord Healthcare S.L.U., Generic, Generic of Alimta, Rapporteur: John Joseph Borg Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Plegridy - peginterferon beta-1a - EMEA/H/C/002827/II/0067 Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.

Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0017/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 21.07.2022, 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0185 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 14.07.2022. Request for Supplementary Information adopted on 12.05.2022.	Positive Opinion adopted by consensus on 14.07.2022.
Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0188 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 14.07.2022.	Request for supplementary information adopted with a specific timetable.
Puregon - follitropin beta - EMEA/H/C/000086/II/0124 Organon N.V., Rapporteur: Jayne Crowe Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0031/G Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0034 Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Rhokiinsa - netarsudil - EMEA/H/C/004583/II/0010/G Santen Oy, Rapporteur: Jayne Crowe Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Rixubis - nonacog gamma - EMEA/H/C/003771/II/0044 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Opinion adopted on 21.07.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 21.07.2022.

on 12.05.2022.	
SARCLISA - isatuximab - EMEA/H/C/004977/II/0015 sanofi-aventis groupe, Rapporteur: Paula Boudewina van Hennik Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
Sogroya - somapacitan - EMEA/H/C/005030/II/0004/G, Orphan Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Spectrila - asparaginase - EMEA/H/C/002661/II/0031 medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Stelara - ustekinumab - EMEA/H/C/000958/II/0094/G Janssen-Cilag International N.V., Rapporteur: Jayne Crowe Request for Supplementary Information adopted on 14.07.2022.	Request for supplementary information adopted with a specific timetable.
Supemtek - quadrivalent influenza vaccine (recombinant, prepared in cell culture) - EMEA/H/C/005159/II/0007/G Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 16.06.2022, 10.03.2022.	Positive Opinion adopted by consensus on 21.07.2022.
TAKHZYRO - lanadelumab - EMEA/H/C/004806/II/0030/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 16.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Tigecycline Accord - tigecycline - EMEA/H/C/005114/II/0002/G Accord Healthcare S.L.U., Generic, Generic of Tygacil, Rapporteur: Daniela Philadelphy Opinion adopted on 21.07.2022. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 21.07.2022.

on 31.03.2022, 13.01.2022.	
Trulicity - dulaglutide - EMEA/H/C/002825/II/0064/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0097 MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 02.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0071 AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 02.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0055, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
WS2264 **Humalog-** **EMEA/H/C/000088/WS2264/0194** **Liprolog-** **EMEA/H/C/000393/WS2264/0154** Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder Opinion adopted on 30.06.2022.	Positive Opinion adopted by consensus on 30.06.2022.
WS2275/G **GONAL-f-** **EMEA/H/C/000071/WS2275/0156/G** **Pergoveris-** **EMEA/H/C/000714/WS2275/0078/G** Merck Europe B.V., Lead Rapporteur: Thalia Marie Estrup Blicher Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
WS2285/G	Positive Opinion adopted by consensus on

Humalog- **EMEA/H/C/000088/WS2285/0195/G** **Liprolog-** **EMEA/H/C/000393/WS2285/0155/G** Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder Opinion adopted on 14.07.2022.	14.07.2022.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Bydureon - exenatide - **EMEA/H/C/002020/II/0074** AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (unknown) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC." Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
BYETTA - exenatide - **EMEA/H/C/000698/II/0078** AstraZeneca AB, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add cholelithiasis and cholecystitis to the list of adverse drug reactions (ADRs) with frequency (unknown) based on the cumulative review of pre-clinical and clinical study data, post-marketing data, medical/scientific literature and signal searches in internal and external databases on 'Gallbladder-related disorders' and exenatide. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
Cibinqo - abrocitinib - **EMEA/H/C/005452/II/0002** Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, "Update of sections 4.2 and 4.5 of the SmPC based on results from Drug-Drug Interaction (DDI) study B7451061; A phase 1,	Positive Opinion adopted by consensus on 07.07.2022.

randomised, crossover study to evaluate relative bioavailability of abrocitinib oral suspension and effect of an acid-reducing agent on the bioavailability of abrocitinib commercial tablet and to assess the taste of abrocitinib oral formulations in healthy adult participants aged 18 to 55 years of age. The Package Leaflet is updated in accordance." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 07.04.2022.	
Dificlir - fidaxomicin - EMEA/H/C/002087/II/0049 Tillotts Pharma GmbH, Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC in order to introduce a new posology regimen based on final results from EXTEND study - A Phase IIIb/IV Randomized, Controlled, Open-Label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium difficile Infection in an Older Population. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0019 Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, "Update of section 4.2 of the SmPC to add nausea/vomiting premedication prophylaxis information following procedure II/14 based on analyses from study DS8201-A-U302 (DESTINY-Breast03); this is a Phase 3, multicenter, randomized, open-label, 2-arm, active controlled study in subjects with unresectable and/or metastatic HER2-positive breast cancer previously treated with trastuzumab and a taxane. The Package Leaflet is updated accordingly." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0013, Orphan Novo Nordisk A/S, Rapporteur: Andrea Laslop, "Update of section 4.2 of the SmPC in order to delete the statement in reference to previously untreated patients (PUPs) and section 5.1 of the SmPC in order to update information based on final results from study NN7088-3908; this is an	Request for supplementary information adopted with a specific timetable.

open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of turoctocog alfa pegol (N8-GP) in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 21.07.2022.	
GONAL-f - follitropin alfa - EMEA/H/C/000071/II/0155 Merck Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.1, 4.2, 4.3, 4.4, 4.7, 5.1, 5.2 and 6.1 of the SmPC to revise the definition of severe LH and FSH deficiency, aligning with current medical guidelines and clinical practice, to clarify follicular development as the treatment target and the use of GONAL-f in Medically Assisted Reproduction procedures for healthcare providers, and clarification of the pharmacokinetic and pharmacodynamic properties of follitropin alfa. These proposed revisions align with the CHMP positive opinion, dated 14 October 2021, for the Type II variation to update the SmPC for Pergoveris for the same indication (EMA/H/C/000714/II/0075), as Pergoveris is comprised of a fixed 2:1 ratio of follitropin alfa and lutropin alfa (r-hLH). The package leaflet is updated accordingly. In addition, the applicant has taken the opportunity to improve the Instructions for Use (IFU) layout and to implement the Medical Device Regulation in the IFU." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Hepcludex - bulevirtide - EMEA/H/C/004854/II/0011, Orphan Gilead Sciences Ireland Unlimited Company, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC in order to move the warnings for the ADRs 'Increase of bile salts' and 'Administration site reactions' to section 4.8 of the SmPC as additional describing information to the listed PTs, together with the addition of a new ADR: hypersensitivity reactions (including anaphylactic reaction). Further to a safety	Positive Opinion adopted by consensus on 07.07.2022.

review based on pooled data from clinical trials and post-marketing experience, editing of existing ADRs in section 4.8 was also carried out. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to bring it in line with the EU QRD template v10.2." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 31.03.2022.	
IBRANCE - palbociclib - EMEA/H/C/003853/II/0038/G Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, "C.I.4: Update of section 5.3 of the SmPC in order to update the primary target organ findings and development toxicity wording. In addition, the MAH took the opportunity to update the list of local representatives (Belgium, Luxembourg, Germany and the Netherlands) in the Package Leaflet. A.6: Update of Palbociclib ATC code based on the last revised classification of the Cyclin-dependent kinase (CDK) inhibitors made by the WHO." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 02.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0074 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the information related to Paediatrics following assessment done in procedure P46/035, based on results from the paediatric study LYM3003 "A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma". The Package Leaflet is updated accordingly." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0075 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to incorporate information specific for	Request for supplementary information adopted with a specific timetable.

dose modifications for non-cardiac events and events of cardiac failure or cardiac arrhythmias events based on data pool from clinical studies which included 4 Phase II (PCYC-1102-CA, PCYC-1104-CA, PCYC-1118E, PCYC-1142-CA) and 8 Phase III studies (PCYC-1112-CA, PCYC-1115-CA, CLL3001, PCYC-1130-CA, MCL3001, PCYC-1127-CA, CLL3011, and MCL3002)." Request for Supplementary Information adopted on 21.07.2022.	
Jardiance - empagliflozin - EMEA/H/C/002677/II/0062/G Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Provision of the final CSR for study EMPULSE (1245-0204), a multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical benefit, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE); In addition, the MAH took the opportunity to implement editorial changes in the SmPC." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 28.04.2022, 10.02.2022.	Positive Opinion adopted by consensus on 21.07.2022.
JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0053/G Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Update of section 4.2 of the SmPC to introduce a heterologous booster dose of JCOVDEN following priming with another adenoviral vector-based vaccine and an inactivated whole virion COVID-19 vaccine based on literature evidence from studies COV-BOOST and RHH-01, respectively. Update of sections 4.8 and 5.1 of the SmPC to include safety and immunogenicity data of JCOVDEN as homologous and heterologous booster dose based on data from studies COV2008, a randomised, double-blind Phase 2 study and literature evidence from studies COV-BOOST, RHH-001 and DMID 21-0012. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable. See 9.1
JEMPERLI - dostarlimab -	Positive Opinion adopted by consensus on

EMEA/H/C/005204/II/0007 GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to update dose modifications recommendations in immune related adverse reactions, amend existing warnings, and add further immune-related ADRs to the list of adverse drug reactions (ADRs), with different frequencies, based on data from company sponsored trials and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make minor changes to sections 4.6 and 5.2 of the SmPC and to update the list of local representatives in the Package Leaflet. Changes are also made to the PI to bring it in line with the current QRD template version and excipients guideline." Request for Supplementary Information adopted on 22.04.2022, 27.01.2022.	21.07.2022.
Jyseleca - filgotinib - EMEA/H/C/005113/II/0008 Galapagos N.V., Rapporteur: Kristina Dunder, "C.I.4 - Update of sections 4.4 and 4.8 of the SmPC in order to update the risk factors for viral reactivation, add recommendation of prophylactic zoster vaccination prior to treatment, add lymphopenia to the list of adverse drug reactions (ADRs) with frequency common, update the information on serum phosphate and the experience from the long-term extension studies based on interim results from study GS-US-417-0304 (FINCH 4); this is a Multicenter, Double-Blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis; the Package Leaflet is updated accordingly." Opinion adopted on 30.06.2022. Request for Supplementary Information adopted on 22.04.2022, 13.01.2022, 09.09.2021.	Positive Opinion adopted by consensus on 30.06.2022.
Koselugo - selumetinib - EMEA/H/C/005244/II/0006/G, Orphan AstraZeneca AB, Rapporteur: Alexandre Moreau, "Submission of the reports for the long-term efficacy and safety updates from study D1532C00057: SPRINT Phase I and SPRINT Phase II Stratum 1 to fulfil the Specific Obligations SOB/003 and SOB/002,	Request for supplementary information adopted with a specific timetable.

respectively, listed in the Annex II of the Product Information. This is a phase I/II study of the mitogen activated protein kinase kinase (MEK) 1 inhibitor selumetinib (AZD6244; HYD-Sulfate) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).” Request for Supplementary Information adopted on 21.07.2022.	
Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0025 AstraZeneca AB, Rapporteur: Silvijus Abramavicius, “Update of section 4.5 of the SmPC in order to add drug-drug interaction information based on final report for interventional study D9480C00012, “A Two-Cohort, Randomised Sequence, Crossover, Open-label Study to Assess the Effect of a Single Dose of Sodium Zirconium Cyclosilicate (SZC) on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects”. The Package Leaflet is updated accordingly. In addition, the MAH is also taking this opportunity to update the contact details of the local representatives in the Package Leaflet.” Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Methylthioninium chloride Proveblue - methylthioninium chloride - EMEA/H/C/002108/II/0052/G Provepharm SAS, Rapporteur: Kristina Dunder, “-Update of sections 4.2 and 5.2 of the SmPC in order to change the posology recommendations in patients with renal and hepatic impairment and update the pharmacokinetic information respectively, based on results from: an open-label, parallel group, population-matched, single-dose study to investigate the influence of renal impairment on the pharmacokinetics of ProvayBlue (Study Report PVP-2016006). The package leaflet and labelling are updated accordingly. The applicant takes this opportunity to update the Product Information according to the QRD template v10.1 and v10.2. -Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with other medicinal products and update the pharmacokinetic information respectively, based	Request for supplementary information adopted with a specific timetable.

on results from: an open-label, randomized, two-period, crossover study to assess the effect of a single dose of methylene blue 5 mg/ml on the pharmacokinetics of the probe drugs midazolam, caffeine, warfarin, omeprazole and dextromethorphan in healthy subjects (Study Report PVP-2016004). The package leaflet and labelling are updated accordingly." Request for Supplementary Information adopted on 21.07.2022, 22.04.2022, 16.12.2021.	
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0011/G Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Grouped variation: - C.I.4 (Type II): Update of section 5.1 of the SmPC in order to introduce data on clinical efficacy against the Omicron variant of concern, based on data from study 2019nCoV-101 (Parts 1 and 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and published literature. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information. - C.I.13 (Type II): Submission of the final clinical report from study 2019nCoV-101 (Part 1), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988). This submission addresses the post-authorisation measures MEA 009, REC 041 and REC 042."	Request for supplementary information adopted with a specific timetable. See 9.1

Request for Supplementary Information adopted on 21.07.2022.	
Oncaspar - pegaspargase - EMEA/H/C/003789/II/0048 Les Laboratoires Servier, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 4.4 of the SmPC in order to add advice on premedication to reduce the cases of hypersensitivity reactions based on literature review and guidelines. The Package Leaflet is updated accordingly." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0012/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "C.I.13 (type II): Submission of the whole body autoradiographic study report in rats with PF-07321332 (alone). C.I.13 (type II): Update of section 5.3 of the SmPC to indicate that no adverse effects were observed during the pre-and postnatal development study based on final study report for the pre- and postnatal development (21GR149)." Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0112 Zr Pharma& GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.8 of the SmPC in order to include information on post-treatment recovery in growth based on final results from study YV25718 listed as a category 3 study in the RMP; this is a Phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO0258310) compared to untreated control in children with HBeAg-Positive Chronic Hepatitis B in the immune active phase. The RMP version 9.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the Package Leaflet." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Piqray - alpelisib - EMEA/H/C/004804/II/0012	Positive Opinion adopted by consensus on

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with CYP3A4 inducers based on study BYL719A2110, a drug-drug interactions study that evaluated the PK of alpelisib when administered alone or with rifampin, a strong CYP3A4 inducer, in healthy participants." Opinion adopted on 21.07.2022.	21.07.2022.
Piqray - alpelisib - EMEA/H/C/004804/II/0013 Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of the SmPC sections 4.6 and 5.3 in order to add fertility data based on studies 2070119 "BYL719: Oral (Gavage) Study of Fertility in the Male Rat" and 2070120 "BYL719: Oral (Gavage) Study of Fertility and Early Embryonic Development in the Female Rat"." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Regkirona - regdanvimab - EMEA/H/C/005854/II/0005 Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update the description of Phase 3 of study CT-P59 3.2 following finalisation of the clinical study report from study CT-P59 3.2 Part 2." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
REKAMBYS - rilpivirine - EMEA/H/C/005060/II/0012 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.2 of the SmPC in order to expand oral bridging options for missed planned injections of cabotegravir and rilpivirine based on studies 201584 (FLAIR), 207966 (ATLAS-2M), 200056 (LATTE 2) and 201585 (ATLAS). The Package Leaflet is updated accordingly. In addition, the MAH is also taking this opportunity to introduce editorial changes." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
RYBREVANT - amivantamab - EMEA/H/C/005454/II/0001	Positive Opinion adopted by consensus on 07.07.2022.

Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add hypokalaemia and hypomagnesaemia to the list of adverse drug reactions (ADRs), with the frequency common, based on an updated analysis of data submitted during the marketing authorisation procedure. The Package Leaflet is updated accordingly. In addition, the MAH proposed to update the current information in section 4.2 of the SmPC to improve clarity and provide more specific guidance. The MAH also took the opportunity to introduce editorial changes in section 4.8 of the SmPC." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 07.04.2022.	
Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267/II/0009 Gedeon Richter Plc., Rapporteur: Paula Boudewina van Hennik, "Update of sections 5.3 and 6.6 of the SmPC based on final results from MVT-601-9030_Relugolix_ZEOGRT_Study (Rec); this is a fish, full life cycle test performed in the context of the Environmental Risk Assessment of relugolix. The Package Leaflet is updated accordingly." Opinion adopted on 30.06.2022.	Positive Opinion adopted by consensus on 30.06.2022.
Spikevax - elasomeran - EMEA/H/C/005791/II/0057 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the Spikevax SmPC to include a 50 µg booster dose for adolescents 12 to 18 years of age, based on the extrapolation of safety and efficacy data from young adults (18 to 24 years of age). The package leaflet is updated accordingly." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 19.05.2022, 22.04.2022.	Positive Opinion adopted by consensus on 21.07.2022. See 9.1
Spikevax - elasomeran - EMEA/H/C/005791/II/0066 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.5 and 5.1 of the SmPC in order to introduce new clinical data regarding the co-administration of Spikevax with a high-dose quadrivalent influenza vaccine (QIV-HD), based on final	Request for supplementary information adopted with a specific timetable. See 9.1

results from study QHD00028 (NCT04969276), a Phase II, Open-label Study to 'Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine'." Request for Supplementary Information adopted on 21.07.2022.	
Spikevax - elasomeran - EMEA/H/C/005791/II/0073 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "C.I.11.b -To update Annex IIE of the Spikevax Product Information to delete SO3. Additional active substance and finished product stability data and review of the active substance and finished product specifications following further manufacturing experience have already been submitted and assessed in the context of previous procedures and are now considered fulfilled." Opinion adopted on 12.07.2022.	Positive Opinion adopted by consensus on 12.07.2022.
TAGRISSO - osimertinib - EMEA/H/C/004124/II/0047 AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.2 of the SmPC based on final results from studies ODIN-BM and ODIN-HV; these are two phase I clinical pharmacology studies conducted in EGFRm+ NSCLC patients (ODIN-BM) and healthy volunteers (ODIN-HV) to determine osimertinib blood-brain barrier (BBB) penetration and brain distribution in patients with brain metastases and healthy volunteers with an intact BBB, respectively." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
TECFIDERA - dimethyl fumarate - EMEA/H/C/002601/II/0078 Biogen Netherlands B.V., Rapporteur: Martina Weise, "Submission of the final report from study 109MS408; upon request by the PRAC as per final PSUR assessment report of procedure EMEA/H/C/PSUSA/00010143/20213. This is a Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl	Positive Opinion adopted by consensus on 14.07.2022.

Fumarate) on Multiple Sclerosis Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing Remitting Multiple Sclerosis in the Real-World Setting (PROTEC)." Opinion adopted on 14.07.2022.	
Vaxchora - cholera vaccine, oral, live - EMEA/H/C/003876/II/0013 Emergent Netherlands B.V., Rapporteur: Ingrid Wang, "Type II - C.I.4, to update section 6.6 of the SmPC to add the use of carbonated bottled water to reconstitute the vaccine in addition to non-carbonated bottled water. The package leaflet and labelling are updated accordingly. The applicant took the opportunity to submit a corrected Annex A in all languages, which currently presents an inconsistency in the way the strength was stated at MAA approval (as detailed in SmPC)." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0031 AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the final study report for MS1222-0002 "In Vitro Assay to Determine Release of Spike Protein From Transduced Cells" to fulfil the imposed study as reflected in Annex II of the product information and the RMP. As a result, Annex II of the product information is being updated to remove this study. The MAH is taking the opportunity to provide two additional studies linked to support the investigation on the platelet activation: the final study report for MS1222-0001 "Computational Prediction of Spike Protein Interaction with Platelet Factor 4 (PF4)" which is the first report requested within the required studies for "in vitro interaction of AZD1222 or spike protein with PF4 and/or platelets" as reflected in the RMP; and the study report for 520447 "Investigative Vaccine Study in the Mouse" to evaluate spike protein levels and haematology parameters." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 23.06.2022, 13.01.2022, 23.09.2021.	Positive Opinion adopted by consensus on 21.07.2022.
Vocabria - cabotegravir - EMEA/H/C/004976/II/0012 ViiV Healthcare B.V., Rapporteur: Jean-Michel	Request for supplementary information adopted with a specific timetable.

Race, "Update of section 4.2 of the SmPC to introduce an alternative oral therapy for bridging between planned missed injections of cabotegravir and rilpivirine (monthly and every 2 months), based on a retrospective safety analysis of pooled data from 29 subjects in 3 clinical studies (Phase III studies: 201584, 207966, and 200056). In addition, the Package Leaflet is updated accordingly. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet." Request for Supplementary Information adopted on 21.07.2022.	
Vyxeos liposomal - daunorubicin / cytarabine - EMEA/H/C/004282/II/0030, Orphan Jazz Pharmaceuticals Ireland Limited, Rapporteur: Johanna Lähteenvuo, "Update of sections 4.2, 4.4 and 5.2 of the SmPC to amend information and delete the existing warning for patients with renal impairment based on the final results from study CPX351-102 (PMR2): a phase 1, open-label, PK and safety study to evaluate the potential impact of renal impairment on the pharmacokinetics and safety of CPX-351 (Daunorubicin and Cytarabine) liposome for injection treatment in adult patients with hematologic malignancies." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 12.05.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Wegovy - semaglutide - EMEA/H/C/005422/II/0003/G Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to update the description of the pharmacodynamic effects and clinical efficacy and safety based on final results from interventional studies: Trial 4378 (STEP 5) which compared the two-year effect of semaglutide 2.4 mg once weekly versus placebo; Trial 4576 (STEP 8) which compared semaglutide s.c. 2.4 mg once weekly to liraglutide s.c. 3.0 mg once daily and Trial 4373 extension (STEP 1ext) which explored the change in body weight, cardiovascular risk factors and glucose metabolism in subjects who completed 68 weeks of treatment (semaglutide	Positive Opinion adopted by consensus on 21.07.2022.

2.4 mg or placebo) followed by a 52-week off-treatment period." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 02.06.2022.	
Xevudy - sotrovimab - EMEA/H/C/005676/II/0005 Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.4 and 5.1 of the SmPC based on final results from study PC-7831-0157. This is a pharmacology study to determine the neutralisation activity of sotrovimab against SARS-CoV-2 pseudotyped virus expressing the Omicron BA.2.12.1, Omicron BA.4, or Omicron BA.5 spike proteins." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
WS2249 **Delstrigo-EMEA/H/C/004746/WS2249/0029** **Pifeltro-EMEA/H/C/004747/WS2249/0022** Merck Sharp & Dohme B.V., Lead Rapporteur: Filip Josephson, "Update of section 5.1 of SmPC based on two non-clinical studies (study PD011: Assessment of in vitro antiviral activity against HIV-1 Resistant mutant, Y318F, alone and in combination with 12 other NNRTI mutants and study PD012: In vitro antiviral activity of doravirine (MK-1439) Against a panel of viruses bearing NNRTI resistance-associated Mutations). In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet." Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
WS2253 **Eucreas-EMEA/H/C/000807/WS2253/0096** **Galvus-EMEA/H/C/000771/WS2253/0076** **Icandra-EMEA/H/C/001050/WS2253/0100** **Jalra-EMEA/H/C/001048/WS2253/0078** **Xiliarx-EMEA/H/C/001051/WS2253/0077** **Zomarist-EMEA/H/C/001049/WS2253/0098** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Mari Thorn, "Update of section 4.8 of the SmPC in order to add the new ADRs 'cutaneous	Positive Opinion adopted by consensus on 07.07.2022.

vasculitis' with the frequency "not known". The Package Leaflet has been updated accordingly." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 05.05.2022.	
WS2259 **DuoPlavin-** **EMEA/H/C/001143/WS2259/0063** **Iscover-** **EMEA/H/C/000175/WS2259/0149** **Plavix-EMEA/H/C/000174/WS2259/0147** sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, "Update of section 4.4 of the SmPC in order to update an existing warning on 'Bleeding and haematological disorders' by adding a statement on triple antiplatelet therapy (clopidogrel + aspirin + dipyridamole) for stroke secondary prevention. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0002 Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC to add information regarding the co-administration of Apexxnar with seasonal quadrivalent influenza vaccine (QIV) based on final study results from study B7471004, "A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 valent Pneumococcal Conjugate Vaccine (20vPnC) When Coadministered with Seasonal Inactivated Influenza Vaccine (SIIV) in Adults ≥65 Years of Age." listed as a category 3 study in the RMP. The Package Leaflet is updated accordingly. The updated RMP version 1.1 has also been submitted." Request for Supplementary Information adopted on 21.07.2022, 19.05.2022.	Request for supplementary information adopted with a specific timetable.
Cibinqo - abrocitinib - EMEA/H/C/005452/II/0001 Pfizer Europe MA EEIG, Rapporteur: Kristina	Request for supplementary information adopted with a specific timetable.

Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015. The RMP version v1.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the contact details of the local representatives in the Package Leaflet." Request for Supplementary Information adopted on 07.07.2022, 07.04.2022.	
CRYSVITA - burosumab - EMEA/H/C/004275/II/0028, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update the frequency of the adverse drug reactions, to split immunogenicity data into paediatric and adult populations and to update clinical efficacy in paediatric patients, upon request by the CHMP following the assessment of PAM procedures P46/006 and P46/007 and type II variations II/04 and II/10/G, based on the final results from studies UX023-CL201, UX023-CL205 and UX023-CL301. The Package Leaflet was updated accordingly. As a consequence of the provision of the final CSR for study UX023-CL205, the last remaining specific obligation was deleted from the Annex II. This was an open-label, phase 2 study undertaken to assess the safety, pharmacodynamics, and efficacy of KRN23 in paediatric patients between 1 and 4 years old with X-linked Hypophosphataemia (XLH). With the fulfilment of this specific obligation the MAH is requesting for the Crysvita MA to no longer be subject to specific obligations. The RMP version 5.0 was agreed." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 22.04.2022.	Positive Opinion adopted by consensus on 21.07.2022. See 9.1
Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/II/0057 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the clinical study report and supporting modular summaries for study GS-US-311-1269 'Phase 2/3, Open Label, Multi-	Positive Opinion adopted by consensus on 07.07.2022.

Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV 1 Infected Children and Adolescents Virologically Suppressed on a 2 NRTI Containing Regimen' in fulfilment of the milestone for the Category 3 additional pharmacovigilance activity to address the safety concern of long-term safety information in adolescents (missing information) as detailed in the Descovy EU Risk Management Plan (RMP). The RMP was amended as version 7 in line with this submission and to update the list of safety concerns." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 07.04.2022.	
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0010, Orphan Novo Nordisk A/S, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.4 and 4.8 of the SmPC to add a new warning and update the list of ADRs based on a validated safety signal concerning a lack of factor VIII activity in patients switching from a similar factor VIII product to Esperoct. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to align it with the latest QRD template version 10.2. The RMP version 2.1 has also been submitted." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 24.03.2022.	Positive Opinion adopted by consensus on 21.07.2022.
EXJADE - deferasirox - EMEA/H/C/000670/II/0082/G Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.13: Submission of the final report from the Calypso study (CICL670F2202) listed as a category 3 study in the RMP. This is a randomized, openlabel, multicenter, two arm, Phase II study to evaluate treatment compliance, efficacy and safety of deferasirox (granules) in pediatric patients with iron overload. The RMP version 20.0 has also been submitted. C.I.11.b: Submission of an updated RMP version 20.0 with the following changes: to remove the	Positive Opinion adopted by consensus on 21.07.2022.

risk of 'medication error' from the Exjade RMP and to remove the information related to the discontinuation of Exjade Dispersible Tablets in the EU." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 07.04.2022.	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0010/G, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "- Update of section 5.3 of the SmPC in order to update the non-clinical information following the study 20147822 (A 6-month Carcinogenicity Study of Fenfluramine Hydrochloride in Mice). - Update of section 5.3 in order to update the non-clinical information following the study 8001993 (A 2-year Oral Gavage Carcinogenicity Study of Fenfluramine Hydrochloride in Rats). - Submission of the final report of study 20147821 (Dose range finding study for 20147822). - Submission of the final report of study 20166554 (Dose range finding study for 20147822). - Submission of the final report of study 2021006-Z001-01 (In-vitro Evaluation of Potential Melanin Binding by Fenfluramine and Norfenfluramine). An RMP version 2.4 has also been agreed." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Fintepla - fenfluramine - EMEA/H/C/003933/II/0011/G, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, "- Update of sections 4.2 and 5.2 of the SmPC to include the relevant information regarding patients with renal impairment following the study 1902 (Pharmacokinetic study of fenfluramine hydrochloride in subjects with varying degrees of impaired and normal renal function) - Update of sections 4.4 and 4.5 of the SmPC in order to reflect the relevant information on CYP1A2 or CYP2B6 or CYP2D6 inducers following the study 1904 (Pharmacokinetic drug-drug interaction study of fenfluramine hydrochloride	Request for supplementary information adopted with a specific timetable.

with and without fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor) and rifampin (CYP2B6 inducer) in healthy subjects). An RMP version 2.2 has also been submitted." Request for Supplementary Information adopted on 07.07.2022, 10.03.2022.	
Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0047, Orphan Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final report from study BO21223/GALLIUM listed as a category 3 study in the RMP. This is an open-label, international, multicenter, randomized, Phase III study to investigate the efficacy and safety of obinutuzumab administration at standard infusion rate plus chemotherapy followed by obinutuzumab maintenance therapy for responders (G-chemo arm) compared with rituximab plus chemotherapy followed by rituximab maintenance therapy for responders (R-chemo arm) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (iNHL).The RMP version 9.0 has also been submitted." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 21.07.2022.
HyQvia - human normal immunoglobulin - EMEA/H/C/002491/II/0078 Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety data in paediatric population based on final results from study 161504 – Post-Authorisation Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases, listed as a category 3 study in the RMP. This is a paediatric interventional Phase 4 study performed to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD). In addition, the MAH is taking this opportunity to update Annex II-D of the PI following procedure EMEA/H/C/002491/II/0070/G. The RMP version 13.1 has also been submitted."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 07.07.2022.	
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0069 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of the SmPC section 4.4 to include information on fatal and serious cardiac arrythmias and cardiac failure, relevant warnings and periodical monitoring of patients and update of the SmPC section 4.8 to include cardiac arrest as an ADR following a safety assessment for increased risk of sudden death/cardiac death with the use of ibrutinib. Section 2 of the PL has been updated accordingly. Typographical errors have been corrected throughout the PI. The revised RMP version 19.4 has been submitted." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 19.05.2022, 27.01.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0064 Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study BO28407 (KAITLIN): A randomized, multicenter, open-label, Phase III trial comparing trastuzumab plus pertuzumab plus a taxane following anthracyclines versus trastuzumab emtansine plus pertuzumab following anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer listed as a category 3 study in the RMP. The RMP version 15.0 has also been submitted." Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0017/G, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4 Update of section 5.3 of the SmPC in order to update the non-clinical information based on final results from a 2-year oral carcinogenicity study in rats (VX-445-TX-015) evaluating the carcinogenic potential of up to 10 mg/kg/day of elexacaftor. An updated RMP (version 6.0) has	Request for supplementary information adopted with a specific timetable.

also been submitted to include the completion of the 2-year carcinogenicity study in rats as well as to update the post-market pregnancy safety information collection form following EMEA/H/C/WS2048. C.I.13 To submit the final report of Tezacaftor Juvenile Toxicity study (VX-661-TX-038).” Request for Supplementary Information adopted on 07.07.2022, 05.05.2022, 10.02.2022.	
Lamzede - velmanase alfa - EMEA/H/C/003922/II/0027, Orphan Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser, “Update of section 4.2 of the SmPC in order to include the home infusion statement, following the assessment of PSUSA/00010677/202009, based on results from LAMAN-07, Sparkle and Italian Patient Support Program (PSP). The Package Leaflet and Annex II are updated accordingly. The RMP version 9.1 has also been submitted.” Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Lorviqua - lorlatinib - EMEA/H/C/004646/II/0022 Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Nikica Mirošević Skvrce, “Submission of an updated RMP version 5.0 to revise plans for conduct of hepatic impairment studies. The RMP is updated to reflect the hepatic impairment study B7461009 “A Phase 1 Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety of Lorlatinib in Advanced Cancer Patients” termination and to include new hepatic impairment study B7461040 “A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate The Plasma Pharmacokinetics and Safety of Lorlatinib in Participants with Moderate and Severe Hepatic Impairment Relative to Participants with Normal Hepatic Function”.” Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Myalepta - metreleptin - EMEA/H/C/004218/II/0025, Orphan Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam	Positive Opinion adopted by consensus on 21.07.2022.

Przybylkowski, "Submission of an updated RPM version 2.1. The applicant is proposing an alternative study to the currently agreed protocol for Specific Obligation SOB002 (AEGR-734-002) due to the challenges of implementing the existing protocol. Annex II is being updated accordingly. The MAH took the opportunity to update the RMP in line with the outcome of previous procedures and to include editorial changes." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 24.03.2022.	
Natpar - parathyroid hormone - EMEA/H/C/003861/II/0042, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the updated protocol from study SHP634-403 listed as a Specific Obligation in the Annex II of the Product Information with twice-daily (BID) as the proposed alternative dosing regimen to be evaluated. This is a Randomized, 2-Arm, Double-Blind, Phase 4 Study to Evaluate Once Daily (QD) Versus Twice Daily (BID) Administration of Recombinant Human Parathyroid Hormone (rhPTH[1-84]; NATPARA) for the Treatment of Adults with Hypoparathyroidism (HPT). The Annex II and the RMP (submitted version 3.4) are updated accordingly." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014 Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a 0.5 mL third dose for Nuvaxovid, to boost subjects that have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an authorised mRNA or adenoviral vector vaccine (heterologous booster dose), based on interim data from study 2019nCoV-101 (Part 2), a Phase 1/2, Randomized, Observer-Blinded Study to	Request for supplementary information adopted with a specific timetable. See 9.1

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), final data from study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and data from the COV-BOOST study (Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial); the Package Leaflet is updated accordingly. The RMP version 1.2 has also been submitted. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information." Request for Supplementary Information adopted on 21.07.2022.	
Ontozry - cenobamate - EMEA/H/C/005377/II/0009 Angelini S.p.A., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.3 of the SmPC in order to update information on toxicity to reproduction and development based on final results from non-clinical study "Effects of Cenobamate (YKP3089) on Embryo-Foetal Development in Rats after Twice Daily Oral Administration". The RMP version 3.0 has been agreed." Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
Raxone - idebenone - EMEA/H/C/003834/II/0031, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.2, 4.4, 4.9 and 5.1 of the SmPC based on the final study report from the PAROS study SNT-IV-003 (SOB003; listed as a cat 2 study in the RMP): "A non-interventional study of clinical experience in patients prescribed Raxone for the	Positive Opinion adopted by consensus on 21.07.2022.

treatment of Leber's Hereditary Optic Neuropathy (LHON)". Annex II is updated in accordance. A revised RMP version 1.17 was also submitted." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 24.03.2022.	
Replagal - agalsidase alfa - EMEA/H/C/000369/II/0117 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.2 and 6.6 of the SmPC in order to add self-administration by a trained patient and/or a caregiver as a new method of administration. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. The RMP version 0.1 has also been submitted." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 23.06.2022, 24.03.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Rubraca - rucaparib - EMEA/H/C/004272/II/0029 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.4, 4.8 and 5.1 of the SmPC based on final results from study CO-338-043 (ARIEL4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.1 has also been submitted. With this variation application, the MAH requests for the Rubraca marketing authorisation to no longer be subject to specific obligations. The SmPC, Annex II and PL are updated accordingly. In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1." Request for Supplementary Information adopted on 21.07.2022, 24.03.2022, 11.11.2021.	Request for supplementary information adopted with a specific timetable. See 9.1
Rydapt - midostaurin - EMEA/H/C/004095/II/0024, Orphan Novartis Europharm Limited, Rapporteur: Paula	Request for supplementary information adopted with a specific timetable.

Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.11.b Submission of the final report from study CPKC412E2301 listed as an obligation in the Annex II of the Product Information. This is a Phase III study to investigate the efficacy in elderly patients. A final pharmacogenomic report is also provided to fulfil MEA004. The Annex II and the RMP (submitted version 7.0) are updated accordingly." Request for Supplementary Information adopted on 07.07.2022, 10.03.2022.	
Trecondi - treosulfan - EMEA/H/C/004751/II/0012, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with regards to CYP3A4, CYP2C19 and P-gp including physiologically based pharmacokinetic (PBPK) modelling. Version 1.0 of the RMP has also been submitted." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Trecondi - treosulfan - EMEA/H/C/004751/II/0013, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of section 5.3 of the SmPC in order to update the description of non-clinical information regarding musculoskeletal and connective tissue disorders in form of lympho-histiocytic infiltration in the skeletal muscles and renal and urinary disorders which show up as haematuria. These new determinations are based on results from study LPT 37259. A revised RMP version 1.0 was also submitted." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
Veklury - remdesivir - EMEA/H/C/005622/II/0034/G Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "Grouping variation to update section 5.1 of the SmPC in relation to information regarding the antiviral activity of Veklury. This submission of the final results of study ACTT-1 with the final	Positive Opinion adopted by consensus on 21.07.2022. See 9.1

sequencing and phenotyping analysis and the full virology report including activity against variants is related to the Specific Obligation 012. Furthermore, Annex II is updated accordingly to reflect the fulfilment of the specific obligations following this submission. Finally, the MAH provided data on the alternative method (i.e., the SARS-CoV-2 replicon system) that can be utilised to allow further testing of the Nsp12 mutation A547V as requested in REC 027 that is also considered fulfilled. The Package Leaflet and the RMP (version 4.0) are updated accordingly. Furthermore, the CHMP is of the opinion that in light of all the data generated throughout all the specific obligations providing a comprehensive dataset, the benefit-risk balance of the above-mentioned medicinal product remains favourable and also considering the evidence of compliance with all specific obligations, the CHMP recommends the granting of a marketing authorisation in accordance with Article 14(1) of Regulation No 726/2004." Opinion adopted on 21.07.2022. Request for Supplementary Information adopted on 22.04.2022.	
Vyndaqel - tafamidis - EMEA/H/C/002294/II/0081, Orphan Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation in the Annex II of the Product Information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
WAYLIVRA - volanesorsen - EMEA/H/C/004538/II/0017/G, Orphan	Positive Opinion adopted by consensus on

Akcea Therapeutics Ireland Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4: Update of sections 4.8 and 5.1 of the SmPC based on the final results from study (ISIS 304801 CS7), a multicentre open label extension study of Volanesorsen administered subcutaneously to patients with Familial Chylomicronemia Syndrome. The Package Leaflet has been updated accordingly. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the PI in order to align with the QRD template and to introduce minor linguistic update to Annex III of the product information to support product launch. C.I.11b. for RMP: Submission of an updated RMP version 2.1 based on the clinical study report addendum: A randomized, double blind, placebo-controlled Phase 3 study of ISIS 304801 administered subcutaneously to patients with Familial Chylomicronemia Syndrome (ISIS 304801 CS6 (APPROACH). C.I.11b. for RMP: Submission of an updated RMP version 2.1 in order to update section V.2 Additional Risk Minimisation Measures in the RMP to reflect a change in the distribution methodology of the educational materials (from a centralised model to a localised model of distribution) and to clarify what is meant by the prescriber kit. C.I.13: Submission of the final report from study ISIS 304801 (CS17). This is a Phase 2/3 double blind, randomized, placebo-controlled study, with an open label extension of ISIS 304801 administered subcutaneously to patients with familial partial lipodystrophy. The RMP version 2.1 has also been submitted." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	07.07.2022.
WS2274 **Relvar Ellipta-** **EMEA/H/C/002673/WS2274/0054** **Revinty Ellipta-** **EMEA/H/C/002745/WS2274/0052** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon, "Submission of the final report from study HZA114971 listed as a category 3 study in the	Request for supplementary information adopted with a specific timetable.

RMP. This is a multicentre randomised, double-blind, placebo-controlled, parallel-group study to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 mcg once daily on growth velocity in prepubertal, paediatric subjects with asthma. The RMP version 11.1 has also been submitted." Request for Supplementary Information adopted on 07.07.2022.	

B.5.4. PRAC assessed procedures

PRAC Led **Brintellix - vortioxetine - EMEA/H/C/002717/II/0037** H. Lundbeck A/S, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the final report from study PASS 16034N listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study (PASS) of vortioxetine in Europe - An analysis of European automated healthcare databases. The RMP version 4.0 has also been submitted." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **Defitelio - defibrotide - EMEA/H/C/002393/II/0058/G, Orphan** Gentium S.r.l., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Grouped application including two type II variations as follows: C.I.13: Submission of the final study report of the DEFIFrance registry: a national, post-registration observational study of the long-term safety and health outcome of patients treated with Defitelio, including patients with severe hepatic VOD after HSCT. This study is listed as a category 3 study in the RMP, and the submission of the study report addresses LEG/011.3. In addition, the MAH took the opportunity to provide two errata to the clinical study reports of studies #R09-1425 and #2006-05. Consequential changes to RMP version 9.2 have been implemented. C.I.11: Submission of an updated RMP version 9.2 in order to remove reproductive toxicity as a potential risk."	Positive Opinion adopted by consensus on 07.07.2022.

Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 07.04.2022.	
PRAC Led **Duavive - estrogens conjugated / bazedoxifene - EMEA/H/C/002314/II/0032** Pfizer Europe MA EEIG, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of an updated RMP version 3.2 in order to reflect the updated study milestones and completion of the post-authorisation safety study of CE/BZA in the United States (US PASS, study B2311060) previously assessed as part of II/0030 (MEA002.15), as well as to update the post-marketing data with the data lock point of 31 October 2021." Request for Supplementary Information adopted on 07.07.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0048/G** Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final reports from four exploratory studies conducted to further characterise the potential mechanisms underlying the important identified risk of thrombosis with thrombocytopenia syndrome (TTS). These studies evaluated the levels of anti-PF4 antibodies using clinical samples, both from Ad26.COV2.S and other non-COVID-19 Ad26-based vaccine clinical studies. Interim results from an additional exploratory study are provided and the submission milestone for the final results has been updated. The RMP version 4.1 has been submitted and updated in line with this procedure and the ongoing procedure EMEA/H/C/005737/II/0047/G. In addition, the MAH removed the important identified risk of anaphylaxis from the list of safety concerns (PSUSA/00010916/202108), updated the routine pharmacovigilance activities section and took the opportunity to implement other administrative updates in the RMP in alignment with procedure EMEA/H/C/005737/II/033. "	Positive Opinion adopted by consensus on 07.07.2022.

Opinion adopted on 07.07.2022.	
PRAC Led **Kuvan - sapropterin - EMEA/H/C/000943/II/0073** BioMarin International Limited, Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final report from study BMN 162-501 KAMPER (formerly EMR700773-001) listed as a category 3 study in the RMP. This is an observational drug registry to assess the long-term safety in subjects treated with Kuvan. The submission of this study addresses the PAM MEA 020. The RMP version 15.1 has also been submitted." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **Lemtrada - alemtuzumab - EMEA/H/C/003718/II/0041** Sanofi Belgium, Duplicate, Duplicate of Lemtrada (WD), PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Update of the RMP (last approved version 9.0) to include a new important identified risk "Autoimmune encephalitis" following a signal on alemtuzumab and autoimmune encephalitis raised in June 2021 and following the outcome of a cumulative review in EMEA/H/C/PSUSA/00010055/202109 procedure. Annex 6 is updated accordingly. In addition, following the requests in procedure EMEA/H/C/003718/II/0038, the list of safety concerns is revised to align with the GVP module V, and the safety concern "use during pregnancy" is removed. The agreed RMP version is v.10.1." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 05.05.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **Moventig - naloxegol - EMEA/H/C/002810/II/0038** Kyowa Kirin Holdings B.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of an updated RMP version 7.2 proposing the cancellation of the cat. 3 study	Positive Opinion adopted by consensus on 07.07.2022.

(D3820R00009: An Observational Drug Utilisation PASS of Moventig in selected European populations), following the assessment of MEA 006.11" Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	
PRAC Led **Nucala - mepolizumab - EMEA/H/C/003860/II/0048** GlaxoSmithKline Trading Services Limited, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of an updated RMP version 11 to reflect the proposal to stop the enrolment and to close the pregnancy registry "Mepolizumab Pregnancy Exposure Study 200870: a phase IV, prospective, observational, exposure cohort study of pregnancy outcomes in women (category 3 post authorisation measure in the RMP)" in 2024. The application also includes details of the proposed enhanced data collection for all pregnancies reported as an alternative." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 07.04.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **PecFent - fentanyl - EMEA/H/C/001164/II/0054** Kyowa Kirin Holdings B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP (version 7.1) in line with the outcome of the last PSUR single assessment (PSUSA) procedure (PSUSA 00001369/202004) finalised in January 2021 in order to update the key messages of the educational materials in line with Instanyl (fentanyl). As a result, Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product' is updated accordingly. Finally, the MAH took the opportunity to bring the RMP in line with revision 2 of GVP module V on 'Risk management systems' and the product information in line with the latest quality review of documents (QRD) template (version 10.2). The requested variation proposed amendments to the Annex II and to the Risk Management Plan (RMP)." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 07.07.2022, 10.03.2022, 28.10.2021.	
PRAC Led **Uptravi - selexipag - EMEA/H/C/003774/II/0035** Janssen-Cilag International N.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 9.3 in order to include the amendment of the ongoing EXPOSURE study protocol, to add the EXTRACT study (67896049PAH0002) as an additional pharmacovigilance activity (PASS) and to include the update of the PRAC-approved EDUCATE PASS protocol (assessed in EMEA/H/C/003774/MEA/003.4)." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 05.05.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **Vargatef - nintedanib - EMEA/H/C/002569/II/0044** Boehringer Ingelheim International GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Georgia Gkegka, PRAC-CHMP liaison: Konstantina Alexopoulou, "Submission of an updated RMP version 10.0 in order to remove safety concerns that were classified as important identified risks, important potential risks and missing information, based on cumulative post-marketing experience. The MAH is also proposing an update of the ATC code, an update of post-marketing exposure, the removal of adverse event follow-up forms and an update of search strategies." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 05.05.2022, 10.02.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0049, Orphan** Takeda Pharmaceuticals International AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of final physician data study results for PASS study "Evaluation of the Effectiveness of Risk Minimisation Measures: A Survey among Health Care Professionals and Patient/Caregivers to Assess their Knowledge and Attitudes on Prescribing and Home	Positive Opinion adopted by consensus on 07.07.2022.

Administration Conditions of Velaglucerase Alpha (VPRIV) in 6 European Countries" (EUPASS 14255). An updated RMP version 11.0 was agreed during the procedure, and Annex II was updated accordingly to include new agreed key elements for the educational material." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 05.05.2022, 02.12.2021, 08.07.2021, 11.02.2021, 26.11.2020.	
PRAC Led **Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0033** Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **WS2212** **Effentora-** **EMEA/H/C/000833/WS2212/0060** Teva B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 5.1 in order to reformat the RMP according to the revised guidance on GVP Module V (revision 2) and to implement PRAC comments arising from previous assessments as follows: - Revision of the list of safety concerns; - Implementation of key messages in educational materials adopted by PRAC for Instanyl; - Revision of Annex 6 to include verbatim the text adopted by PRAC for Instanyl as presented in Annex 2 of the PRAC PSUSA AR; - Revision of the use of digital access to educational material; - Explanation of the role of the Health Products	Request for supplementary information adopted with a specific timetable.

Regulatory Authority (HPRA)'s CAPA being no longer found to be a trigger of the current RMP update. The 'additional risk minimisation measures' in the Annex II of the product information have been updated accordingly." Request for Supplementary Information adopted on 07.07.2022, 10.03.2022.	
PRAC Led **WS2216** **Exviera-EMEA/H/C/003837/WS2216/0052** **Maviret-EMEA/H/C/004430/WS2216/0049** **Viekirax-EMEA/H/C/003839/WS2216/0064** AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Opinion adopted on 07.07.2022. Request for Supplementary Information adopted on 10.03.2022.	Positive Opinion adopted by consensus on 07.07.2022.
PRAC Led **WS2222** **Epclusa-EMEA/H/C/004210/WS2222/0064** **Harvoni-EMEA/H/C/003850/WS2222/0104** **Sovaldi-EMEA/H/C/002798/WS2222/0077** **Vosevi-EMEA/H/C/004350/WS2222/0054** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "Submission of the final report from study B20-146 listed as a category 3 study in the RMP. This is a non-imposed joint post-authorisation safety study to evaluate the risk of de novo hepatocellular carcinoma in patients with compensated cirrhosis treated with direct-acting antivirals for chronic hepatitis C (HCC De Novo PASS)." Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.

Request for Supplementary Information adopted on 10.03.2022.	

B.5.5. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0002, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani Opinion adopted on 21.07.2022, 15.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/II/0003, ATMP Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani Request for Supplementary Information adopted on 15.07.2022.	Request for supplementary information adopted with a specific timetable.
Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0053, ATMP Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo Opinion adopted on 21.07.2022, 15.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0058, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 21.07.2022, 15.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0059, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Update of section 5.1 of the SmPC based on a subgroup analysis from CCTL019B2401 (B2401) disease registry listed as a PAES (ANX006) in the Annex II; this is a non-interventional study to evaluate the efficacy and safety of Kymriah in ALL patients below the age of 3 years. In addition, the MAH took the opportunity to update Annex II.D of the SmPC to reflect the fulfilment of the PAES." Request for Supplementary Information adopted on 15.07.2022.	Request for supplementary information adopted with a specific timetable.

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0061/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Request for Supplementary Information adopted on 15.07.2022.	Request for supplementary information adopted with a specific timetable.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0028/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 21.07.2022, 15.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
WS2247 **Tecartus- EMEA/H/C/005102/WS2247/0020** **Yescarta- EMEA/H/C/004480/WS2247/0050** Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus Request for Supplementary Information adopted on 15.07.2022, 13.05.2022.	Request for supplementary information adopted with a specific timetable.

B.5.6. CHMP-PRAC-CAT assessed procedures

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0060, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC in order to update the paediatric statement for the B-cell ALL indication and section 4.4 to update the warning on 'prior treatment with anti-CD19 therapy' as well as sections 4.4 and 4.8 in order to update safety data to reflect the pool of the 3 studies B2202, B2205J and B2001X. The proposed changes are in line with the request of the CHMP following the assessment of P46/012. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct the Complete Response Rate (CRR) 95% Confidence Interval (CI) on Enrolled set for E2202 study presented in Table 8 in section 5.1 of the SmPC. The RMP version 5.0 has also been submitted."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 15.07.2022.	

B.5.7. PRAC assessed ATMP procedures

PRAC Led **Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0051, ATMP** Amgen Europe B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20180062; "Observational Research Study Report (ORSR)" listed as a category 3 study in the RMP. This is a multinational, non-interventional, cross-sectional survey study for the Patients aged ≥ 18 years who have received IMLYGIC at least once in the 3 months prior to completing the survey to evaluate the effectiveness of the patient-directed aRMMS. The primary objective of this study is to evaluate patients' knowledge levels of the key messages included in the IMLYGIC Patient Safety Brochure among patients who receive IMLYGIC." Opinion adopted on 21.07.2022, 15.07.2022. Request for Supplementary Information adopted on 13.05.2022.	Positive Opinion adopted by consensus on 21.07.2022.
PRAC Led **Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0033, Orphan, ATMP** Orchard Therapeutics (Netherlands) BV, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study STRIM-001 "Evaluation of referring healthcare providers' and parents'/carers' understanding of specific risks associated with Strimvelis treatment" listed as a category 3 study in the RMP. The RMP version 6.1 has also been submitted." Opinion adopted on 21.07.2022, 15.07.2022. Request for Supplementary Information adopted on 18.03.2022.	Positive Opinion adopted by consensus on 21.07.2022.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2219/G	Positive Opinion adopted by consensus on

Fluenz Tetra-EMEA/H/C/002617/WS2219/0116/G **Pandemic influenza vaccine H5N1 AstraZeneca-EMEA/H/C/003963/WS2219/0050/G** AstraZeneca AB, Lead Rapporteur: Christophe Focke Opinion adopted on 07.07.2022.	07.07.2022.
WS2239/G **Hexacima-EMEA/H/C/002702/WS2239/0128/G** **Hexyon-EMEA/H/C/002796/WS2239/0132/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 21.07.2022, 12.05.2022.	Request for supplementary information adopted with a specific timetable.
WS2246 **Tivicay-EMEA/H/C/002753/WS2246/0080** **Triumeq-EMEA/H/C/002754/WS2246/0105** ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
WS2251/G **Eucreas-EMEA/H/C/000807/WS2251/0097/G** **Icandra-EMEA/H/C/001050/WS2251/0101/G** **Zomarist-EMEA/H/C/001049/WS2251/0099/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
WS2255 **Juluca-EMEA/H/C/004427/WS2255/0043** **Tivicay-EMEA/H/C/002753/WS2255/0078** **Triumeq-EMEA/H/C/002754/WS2255/0103** ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson Opinion adopted on 30.06.2022.	Positive Opinion adopted by consensus on 30.06.2022.
WS2260 **Stayveer-EMEA/H/C/002644/WS2260/0036** **Tracleer-EMEA/H/C/000401/WS2260/0101** Janssen-Cilag International N.V., Lead	Positive Opinion adopted by consensus on 07.07.2022.

Rapporteur: Alexandre Moreau Opinion adopted on 07.07.2022.	
WS2271/G **Erelzi-** **EMEA/H/C/004192/WS2271/0041/G** **Rixathon-** **EMEA/H/C/003903/WS2271/0058/G** **Riximyo-** **EMEA/H/C/004729/WS2271/0059/G** Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
WS2272/G **Hexacima-** **EMEA/H/C/002702/WS2272/0131/G** **Hexyon-** **EMEA/H/C/002796/WS2272/0135/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
WS2279/G **Ebymect-** **EMEA/H/C/004162/WS2279/0057/G** **Xigduo-** **EMEA/H/C/002672/WS2279/0067/G** AstraZeneca AB, Lead Rapporteur: Kristina Dunder Opinion adopted on 07.07.2022.	Positive Opinion adopted by consensus on 07.07.2022.
WS2282 **Hexacima-** **EMEA/H/C/002702/WS2282/0132** **Hexyon-** **EMEA/H/C/002796/WS2282/0136** Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus	Positive Opinion adopted by consensus on 21.07.2022.
WS2287/G **Filgrastim Hexal-** **EMEA/H/C/000918/WS2287/0064/G** **Zarzio-** **EMEA/H/C/000917/WS2287/0065/G** Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.
WS2290 **Prezista-** **EMEA/H/C/000707/WS2290/0117**	Positive Opinion adopted by consensus on 21.07.2022.

Rezolsta- **EMEA/H/C/002819/WS2290/0048** **Symtuza-** **EMEA/H/C/004391/WS2290/0044** Janssen-Cilag International N.V., Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 21.07.2022.	
WS2292 **Abseamed-** **EMEA/H/C/000727/WS2292/0099** **Binocrit-** **EMEA/H/C/000725/WS2292/0098** **Epoetin alfa Hexal-** **EMEA/H/C/000726/WS2292/0098** Sandoz GmbH, Lead Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 21.07.2022.	Request for supplementary information adopted with a specific timetable.
WS2293 **Lyrica-EMEA/H/C/000546/WS2293/0119** **Pregabalin Pfizer-** **EMEA/H/C/003880/WS2293/0048** Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update sections 4.4 and 4.8 of the SmPC and sections 2, 3 and 4 of the PL, to implement the wording related to the cases of abuse and dependence in patients without a history of substance disorder, following procedures EMEA/H/C/000546/LEG/057 and EMEA/H/C/003880/LEG/009, resulting from EMEA/H/C/PSUSA/00002511/202101." Opinion adopted on 21.07.2022.	Positive Opinion adopted by consensus on 21.07.2022.
WS2295 **Ongentys-** **EMEA/H/C/002790/WS2295/0048** **Ontilyv-EMEA/H/C/005782/WS2295/0002** Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise Opinion adopted on 14.07.2022.	Positive Opinion adopted by consensus on 14.07.2022.

B.5.9. Information on withdrawn type II variation / WS procedure

Carbaglu - carglumic acid - EMEA/H/C/000461/II/0044 Recordati Rare Diseases, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.2 and 4.4 of the SmPC in order to include information on the impact of renal impairment on systemic exposures to Carbaglu following a FDA request, based on final results from study A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Carbaglu in Subjects with Normal and Varying Degrees of Impaired Renal Function. The Package Leaflet is updated accordingly. The RMP version 2.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 23.06.2022. Withdrawal request submitted on 06.07.2022.	The MAH withdrew the procedure on 06.07.2022.
WS2254 **HBVAXPRO-EMEA/H/C/000373/WS2254/0077** **Vaxelis-EMEA/H/C/003982/WS2254/0103** Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus Withdrawal request submitted on 01.07.2022.	The MAH withdrew the procedure on 01.07.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

PRAC Led **Stelara - ustekinumab - EMEA/H/C/000958/II/0091** Janssen-Cilag International N.V., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final safety registry report of CNTO1275PSO4007 "Pregnancy Research Initiative: Exposure to ustekinumab during pregnancy: A review and analysis of birth outcomes from the Swedish, Danish, and Finnish medical birth registers." Consequently, the RMP version 22.1 has been updated." Request for Supplementary Information adopted on 10.06.2022, 10.02.2022.	Request by the applicant for an extension to the clock stop to respond to the RSI adopted in June 2022. The CHMP agreed to the request by the applicant.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

piflufolastat (18f) - EMEA/H/C/005520
imaging in patients undergoing oncologic diagnostic procedures when increased expression of prostate specific membrane antigen is a diagnostic target

dantrolene sodium, hemiheptahydrate - EMEA/H/C/006009, Orphan
Norgine B.V., treatment of malignant hyperthermia (including suspected cases)

degarelix acetate - EMEA/H/C/006048
treatment of prostate cancer

trastuzumab duocarmazine - EMEA/H/C/005654
treatment of HER2 (Human Epidermal Growth Factor Receptor 2)-positive metastatic breast cancer

human albumin solution / gentamicin sulfate - EMEA/H/D/006141
human assisted reproductive techniques including in-vitro fertilisation procedures

melatonin - EMEA/H/C/005603
treatment of primary insomnia

eculizumab - EMEA/H/C/006036
treatment of paroxysmal nocturnal haemoglobinuria

ivosidenib - EMEA/H/C/006174, Orphan
Les Laboratoires Servier, treatment of acute myeloid leukaemia

natalizumab - EMEA/H/C/005752
Therapy for active relapsing remitting multiple sclerosis (RRMS)

in vitro diagnostic medical device - EMEA/H/D/006107
In-vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1)

alpelisib - EMEA/H/C/005468, Orphan
Novartis Europharm Limited, treatment of patients with severe manifestations of PIK3CA-related overgrowth spectrum

atogepant monohydrate -
EMEA/H/C/005871
Prophylaxis of migraine in adults who have at least 4 migraine days per month.

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

COMIRNATY - tozinameran -
EMEA/H/C/005735/X/0138
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst, "Extension application to add a new strength of 3 µg for individuals 6 months to 4 years of age. In addition, the applicant took the opportunity to introduce editorial changes in Annex I, IIIA and IIIB of the PI.
The RMP (version 5.1) is updated in accordance."

Entresto - sacubitril / valsartan -
EMEA/H/C/004062/X/0044/G
Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark, "Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of study PANORAMA-HF (CLCZ696B2319); a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the Package Leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one-year extension of the market protection."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Neparvis - sacubitril / valsartan - EMEA/H/C/004343/X/0042/G Novartis Europharm Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Anette Kirstine Stark, "Extension application to introduce a new pharmaceutical form associated with two new strengths (6 mg/6 mg granules in capsule for opening and 15 mg/16 mg granules in capsule for opening), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of children and adolescents aged one year or older with chronic heart failure with left ventricular systolic dysfunction, based on the results of study PANORAMA-HF (CLCZ696B2319); a multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of sacubitril/valsartan followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of sacubitril/valsartan compared with enalapril in paediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.2 of the SmPC are being updated and the Package Leaflet is updated accordingly. In addition, an updated RMP version 4.0 was provided as part of the application. Further, the MAH requested a one-year extension of the market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Sogroya - somapacitan - EMEA/H/C/005030/X/0006/G, Orphan Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Extension application to add a new strength of 15 mg/1.5 mL solution for injection in pre-filled pen grouped with a type II variation C.I.6 to add a new indication 'Replacement of endogenous growth hormone (GH) in children and adolescents with growth failure due to growth hormone deficiency (GHD)', based on results from the completed main 52-week period of the confirmatory phase 3 trial (4263),	

supported with long-term data from the phase 2 trial (4172), up to week 208 completed. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. A revised RMP version 3.0 was provided as part of the application."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G
Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance."
List of Questions adopted on 22.04.2022.

tabelecleucel - EMEA/H/C/004577, Orphan, ATMP
Atara Biotherapeutics Ireland Limited, treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV^+ PTLD)
List of Questions adopted on 18.03.2022.

abaloparatide - EMEA/H/C/005928
treatment of osteoporosis
List of Questions adopted on 24.03.2022.

miglustat - EMEA/H/C/005695, Orphan
Amicus Therapeutics Europe Limited, treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease
List of Questions adopted on 24.03.2022.

pirfenidone - EMEA/H/C/005862
treatment of Idiopathic Pulmonary Fibrosis (IPF)
List of Questions adopted on 24.03.2022.

cipaglucosidase alfa - EMEA/H/C/005703, Orphan
Amicus Therapeutics Europe Limited, treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

List of Questions adopted on 24.03.2022.

palovarotene - EMEA/H/C/004867, Orphan
Ipsen Pharma, Treatment of fibrodysplasia ossificans progressiva
List of Questions adopted on 16.09.2021.

sugammadex - EMEA/H/C/005935
reversal of neuromuscular blockade induced by rocuronium or vecuronium
List of Questions adopted on 24.03.2022.

vadadustat - EMEA/H/C/005131
Treatment of anaemia
List of Questions adopted on 24.03.2022.

Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G
Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik, "Extension application to introduce a new pharmaceutical form associated with new strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002). The RMP (version 2.0) is updated in accordance."
List of Questions adopted on 22.04.2022.

B.6.4. Annual Re-assessments: timetables for adoption

Bylvay - odevixibat - EMEA/H/C/004691/S/0008, Orphan
Albireo, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

MVABEA - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005343/S/0015
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Qarziba - dinutuximab beta - EMEA/H/C/003918/S/0046, Orphan
EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/S/0012
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

COMIRNATY - tozinameran - EMEA/H/C/005735/R/0137
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/R/0023
Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Lamzede - velmanase alfa - EMEA/H/C/003922/R/0029, Orphan
Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Jan Neuhauser

Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/R/0027
AstraZeneca AB, Rapporteur: Silvijus Abramavicius, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Kirsti Villikka

Lumykras - sotorasib - EMEA/H/C/005522/R/0002
Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/R/0020
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski

Riarify - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004836/R/0022
Chiesi Farmaceutici S.p.A., Informed Consent of

Trimbow, Rapporteur: Janet Koenig, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Jan Neuhauser
Semglee - insulin glargine - EMEA/H/C/004280/R/0040 Viatris Limited, Rapporteur: Martina Weise, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst
Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/R/0057 GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik
Spikevax - elasomeran - EMEA/H/C/005791/R/0074 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen
Tecartus - brexucabtagene autoleucel - EMEA/H/C/005102/R/0025, Orphan, ATMP Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, CHMP Coordinators: Jan Mueller-Berghaus and Ingrid Wang, PRAC Rapporteur: Menno van der Elst
Trydonis - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004702/R/0025 Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Rapporteur: Janet Koenig, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Jan Neuhauser
Zessly - infliximab - EMEA/H/C/004647/R/0025 Sandoz GmbH, Rapporteur: Eva Skovlund, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Mari Thorn

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) -	See 5.1

EMEA/H/C/002596/II/0076
Bavarian Nordic A/S, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include active immunisation against monkeypox and disease caused by vaccinia virus in adults for Imvanex; as a consequence, sections 1, 4.1, 4.2, 4.4, 4.6 and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.2." Opinion adopted on 21.07.2022.

Trulicity - dulaglutide - EMEA/H/C/002825/II/0065
Eli Lilly Nederland B.V., Rapporteur: Martina Weise, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Amelia Cupelli, "Extension of indication to include treatment of type 2 diabetes mellitus (T2DM) in children and adolescents aged 10 to less than 18 years based on final results from study H9X-MC-GBGC; this is a phase 3, double-blind, randomised, multi-centre, placebo-controlled superiority trial to evaluate PK, PD, safety and efficacy of dulaglutide in children from 10 to less than 18 years of age, with an open label extension to evaluate safety. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.1 of the RMP has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Adtralza - tralokinumab - EMEA/H/C/005255/II/0005
LEO Pharma A/S, Rapporteur: Jayne Crowe

Alecensa - alectinib - EMEA/H/C/004164/II/0041
Roche Registration GmbH, Rapporteur: Filip Josephson

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0007/G
Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy

Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0161

Amgen Europe B.V., Rapporteur: Martina Weise

ARIKAYCE liposomal - amikacin - EMEA/H/C/005264/II/0008/G, Orphan
Insmed Netherlands B.V., Rapporteur: Jayne Crowe

Elaprase - idursulfase - EMEA/H/C/000700/II/0101
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege

Erbitux - cetuximab - EMEA/H/C/000558/II/0094/G
Merck Europe B.V., Rapporteur: Filip Josephson

Fortacin - lidocaine / prilocaine - EMEA/H/C/002693/II/0035/G
Recordati Ireland Ltd, Rapporteur: Maria Concepcion Prieto Yerro

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0050, Orphan
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia

Grepid - clopidogrel - EMEA/H/C/001059/II/0054
Pharmathen S.A., Generic, Generic of Plavix, Rapporteur: Nevenka Trsinar Brodt

Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0139
CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0057
Janssen-Cilag International N.V., Rapporteur: Christophe Focke

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0058/G
Janssen-Cilag International N.V., Rapporteur: Christophe Focke

Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0024/G
Bayer AG, Rapporteur: Thalia Marie Estrup Blicher

Kovaltry - octocog alfa - EMEA/H/C/003825/II/0039

Bayer AG, Rapporteur: Kristina Dunder

Lyumjev - insulin lispro - EMEA/H/C/005037/II/0016
Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola

Nuceiva - botulinum toxin type A - EMEA/H/C/004587/II/0027
Evolus Pharma B.V., Rapporteur: Jayne Crowe

Obizur - susoctocog alfa - EMEA/H/C/002792/II/0047/G
Baxalta Innovations GmbH, Rapporteur: Andrea Laslop

Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0035, Orphan
Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa

Ogluo - glucagon - EMEA/H/C/005391/II/0005/G
Tetris Pharma B.V., Rapporteur: Karin Janssen van Doorn

Onpattro - patisiran - EMEA/H/C/004699/II/0027/G, Orphan
Alnylam Netherlands B.V., Rapporteur: Kristina Dunder

Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0019/G
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race

Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0012/G
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia

Prasugrel Mylan - prasugrel - EMEA/H/C/004644/II/0013
Mylan Pharmaceuticals Limited, Generic, Generic of Efient, Rapporteur: Alar Irs

Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMEA/H/C/001104/II/0206/G
Pfizer Europe MA EEIG, Rapporteur: Kristina

Dunder

PREVYMIS - letermovir - EMEA/H/C/004536/II/0028/G, Orphan
Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson

Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0045, Orphan
EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik

Respreeza - human alpha1-proteinase inhibitor - EMEA/H/C/002739/II/0060
CSL Behring GmbH, Rapporteur: Kristina Dunder

RINVOQ - upadacitinib - EMEA/H/C/004760/II/0025/G
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder

Sialanar - glycopyrronium - EMEA/H/C/003883/II/0025/G
Proveca Pharma Limited, Rapporteur: Thalia Marie Estrup Blicher

Tecentriq - atezolizumab - EMEA/H/C/004143/II/0070/G
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia

Tysabri - natalizumab - EMEA/H/C/000603/II/0133
Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0029
Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0104/G
MCM Vaccine B.V., Rapporteur: Christophe Focke

Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0007/G
Merck Sharp & Dohme B.V., Rapporteur: Johann

Lodewijk Hillege

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0076/G
AstraZeneca AB, Rapporteur: Sol Ruiz

Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0009/G
Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise

Vectibix - panitumumab - EMEA/H/C/000741/II/0099
Amgen Europe B.V., Rapporteur: Eva Skovlund

Xenical - orlistat - EMEA/H/C/000154/II/0086
CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Jean-Michel Race

WS2283/G
Eucreas- EMEA/H/C/000807/WS2283/0098/G
Galvus- EMEA/H/C/000771/WS2283/0077/G
Icandra- EMEA/H/C/001050/WS2283/0103/G
Jalra- EMEA/H/C/001048/WS2283/0080/G
Xiliarx- EMEA/H/C/001051/WS2283/0078/G
Zomarist- EMEA/H/C/001049/WS2283/0100/G
Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder

WS2288
Humalog- EMEA/H/C/000088/WS2288/0196
Liprolog- EMEA/H/C/000393/WS2288/0156
Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder

WS2296/G
Infanrix hexa- EMEA/H/C/000296/WS2296/0316/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2300/G
Infanrix hexa- EMEA/H/C/000296/WS2300/0317/G

GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2313
Hexacima-EMEA/H/C/002702/WS2313/0133
Hexyon-EMEA/H/C/002796/WS2313/0137
Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus

WS2319
Nuwiq-EMEA/H/C/002813/WS2319/0049
Vihuma-EMEA/H/C/004459/WS2319/0031
Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

WS2327
Incresync-EMEA/H/C/002178/WS2327/0042
Vipdomet-EMEA/H/C/002654/WS2327/0039
Vipidia-EMEA/H/C/002182/WS2327/0031
Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hillege

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Bavencio - avelumab - EMEA/H/C/004338/II/0035
Merck Europe B.V., Rapporteur: Filip Josephson, "Update of sections 4.2, 5.1 and 5.2 of the SmPC based on final results from study MS100070-0306 following a P46 procedure (EMEA/H/C/004338/P46/009). This is a Phase I, multi-centre, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in paediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumours (including central nervous system tumours) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy. In addition, the MAH took the opportunity to update Annex II section D to be aligned with the EU Educational materials (EM) and the EU Risk Management Plan (RMP).
Furthermore, the MAH took the opportunity to

implement editorial changes."

CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0029

Ipsen Pharma, Rapporteur: Ingrid Wang, "Update of sections 4.4 and 4.8 of the SmPC in order to update special warnings data and information of adverse drug reactions (ADRs) based on results from study XL184-311 (COSMIC-311); study XL184-311 was a Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study of cabozantinib in subjects with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who had progressed during or after prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.
In addition, the MAH is taking this opportunity to propose minor updates to the Package Leaflet."

Calquence - acalabrutinib - EMEA/H/C/005299/II/0013

AstraZeneca AB, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study ACE-CL-309 (A Phase 3 randomized open-label active-control study investigating Calquence for the Treatment of Subjects With Relapsed or Refractory Chronic Lymphocytic Leukaemia) listed as a category 3 study in the RMP."

Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0115

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, "Submission of the final report from study HPV-027 listed as a category 3 study in the RMP to fulfil MEA 024.2; this is a long-term follow-up registry-based cohort study of HPV vaccine effectiveness against cervical pre-cancerous lesions and cervical cancer in a cohort of females previously enrolled from Finland in study HPV-008, as compared to an unvaccinated population-based reference cohort of females from Finland."

Cibinqo - abrocitinib - EMEA/H/C/005452/II/0005

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, "Update of section 4.5 of the SmPC

based on final results from Drug-Drug Interaction (DDI) study B7451092. This is a Phase I, open-label, fixed-sequence, 2-period study to estimate the effect of multiple dose abrocitinib on the pharmacokinetics of single doses of caffeine, efavirenz, and omeprazole in healthy participants."

Darzalex - daratumumab - EMEA/H/C/004077/II/0062, Orphan

Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, "Update of section 4.8 of the SmPC in order to add COVID-19 to the list of adverse drug reactions (ADRs) with frequency uncommon, based on a pooled dataset from the following interventional studies 4767414MMY2004, 54767414MMY3003, 54767414MMY3006, 54767414MMY3008 and 54767414MMY3013. The Package Leaflet is updated accordingly."

Evoltra - clofarabine - EMEA/H/C/000613/II/0077

Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of the Package Leaflet in order to update information regarding breast-feeding based on a comprehensive safety review. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0060

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) based on pooled analyses of clinical safety data from the following Phase III interventional studies: VAC31518COV3001 and VAC31518COV3009; and from the Phase I/II interventional studies: VAC31518COV1001, VAC31518COV1002, VAC31518COV1003 and VAC31518COV2001. The Package Leaflet is updated accordingly."

Keytruda - pembrolizumab - EMEA/H/C/003820/II/0126

Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani, "To update sections 4.2 and 5.2 of the SmPC to include data for patients with moderate hepatic impairment based on

KEYNOTE-240 (a double-blind, randomized, Phase 3 study of pembrolizumab in participants with previously systemically treated advanced HCC) and KEYNOTE-224 (a Phase 2 study of pembrolizumab as monotherapy in participants with advanced HCC). The MAH took the opportunity to make some editorial changes."

Leqvio - inclisiran - EMEA/H/C/005333/II/0011

Novartis Europharm Limited, Rapporteur: Martina Weise, "Submission of the final report from non-clinical study no. 2120284 in order to address a recommendation (REC). This is an in-silico assessment of the cross-tissue mRNA expression of the genes encoding for SULF1, INSYN2B (also referred to as FAM196B), ASGR1 and ASGR2 in tissues in man, monkey, rat and mouse."

Lumeblue - methylthioninium chloride - EMEA/H/C/002776/II/0004

Alfasigma S.p.A., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2 and 5.2 of the SmPC in order to introduce a new posology regimen based on scientific literature."

Lumykras - sotorasib - EMEA/H/C/005522/II/0003

Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC based on results from the enteral feeding tube in vitro study (RPT-574024), undertaken to assess the feasibility of administration of sotorasib 120 mg film-coated tablets through an enteral feeding tube. The Package Leaflet was updated accordingly."

Lumykras - sotorasib - EMEA/H/C/005522/II/0004

Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.5 of the SmPC based on the results of study 2020042, a phase 1 clinical drug interaction study undertaken to assess the effect of concomitant sotorasib administration on the systemic exposure of breast cancer resistance protein (BCRP) transporter substrates. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet."

Lysodren - mitotane -

EMEA/H/C/000521/II/0026 HRA Pharma Rare Diseases, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.4 and 4.8 of the SmPC with new safety information regarding skin reactions (including rash, pruritus, urticaria…) and estrogenic effects in children based on post-marketing safety report and literature. The Package Leaflet is updated accordingly."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0015 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 5.1 of the SmPC in order to add effect on lipids based on results from study C4671001; In addition, the MAH took the opportunity to make an editorial clarification."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0016/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to include the adverse reactions nausea, abdominal pain and malaise based on global safety database of the MAH and Literature Review. The Package Leaflet is updated accordingly."	
Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0017 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study In Vivo Efficacy Of Pf-07321332 As A Single Agent Or In Combination With Ritonavir In Balb/C Mouse-Adapted Sars-Cov-2 Model (PAM 023). The objective of this study was to evaluate whether Ritonavir has in vivo antiviral activity against SARS-CoV-2 and whether combination	

of Ritonavir with PF-07321332 increased the exposure of PF-07321332 in the mouse model and further decreased viral lung replication."	
Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0043, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly."	
Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0044, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.2 and 4.8 of the SmPC with new safety information regarding central nervous system toxicity based on post-marketing safety report and literature."	
QUVIVIQ - daridorexant - EMEA/H/C/005634/II/0004/G Idorsia Pharmaceuticals Deutschland GmbH, Rapporteur: Alexandre Moreau, "Submission of the final report from studies BA-17.030 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rat plasma samples by LC-MS/MS) and study BA-18.023 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rabbit plasma samples by LC-MS/MS). Both studies are part of the same post-authorisation measure evaluating the long-term stability of daridorexant and its metabolites (ACT-776063, ACT776537 and ACT-1016-3307) in rat and rabbit."	
Reblozyl - luspatercept - EMEA/H/C/004444/II/0011, Orphan Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphy, "Update of sections 4.2,	

4.4 and 4.8 of the SmPC in order to include new safety information about Extramedullary Hematopoietic Masses in transfusion-dependent beta-thalassemia patients based on the open-label phase of the ACE-536-B-THAL-001 Phase III study, the long-term follow-up study and post-marketing data. The Package Leaflet is updated accordingly."	
Rozlytrek - entrectinib - EMEA/H/C/004936/II/0012 Roche Registration GmbH, Rapporteur: Armando Genazzani, "Submission of the final integrated analysis report for cardiac risks, listed as a category 3 study in the RMP, in order to fulfil MEA/003. This is an integrated safety analysis report to assess cardiac risks based on GO40782 [STARTRK-2], CO40778 [STARTRK-NG], and BO41932 [TAPISTRY] studies (PAESs)."	
Simponi - golimumab - EMEA/H/C/000992/II/0107 Janssen Biologics B.V., Rapporteur: Kristina Dunder, "Submission of the final report from study MK-8259-038 (Go-BACK) in order to fulfil MEA/30.2. This is a phase 4, randomized, double-blind, parallel-group, withdrawal, post-authorisation efficacy study (PAES) of golimumab in adult participants, aged 18 to 45 years, with active non-radiographic axial spondyloarthritis."	
Soliris - eculizumab - EMEA/H/C/000791/II/0122, Orphan Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, "Submission of the final report from study ECU-NMO-302, a phase III, open-label, extension trial of ECU-NMO-301 to evaluate the safety and efficacy of eculizumab in subjects with neuromyelitis optica spectrum disorder (NMOSD) following procedure II/0105."	
Spikevax - elasomeran - EMEA/H/C/005791/II/0073 Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "C.I.11.b -To update Annex IIE of the Spikevax Product Information to delete SO3. Additional active substance and finished product stability data and review of the active substance and finished product specifications following further manufacturing	See B.5.2

experience have already been submitted and assessed in the context of previous procedures and are now considered fulfilled."

Venclyxto - venetoclax - EMEA/H/C/004106/II/0042

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update data supporting the efficacy of the combined regimen of obinutuzumab and venetoclax (VEN+G; also known as GDC-0199 or ABT-199) versus obinutuzumab plus chlorambucil (GClb) in previously untreated CLL patients based on final results from study BO25323/CLL14; this is a prospective, open-label, multicenter randomized phase 3 trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax (GDC-0199/ABT-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Xarelto - rivaroxaban - EMEA/H/C/000944/II/0096

Bayer AG, Rapporteur: Kristina Dunder, "Submission of the final report from study 15786 (COMPASS LTOLE). This is a phase 3, multicenter, randomized, double-blind, double-dummy, active comparator, event-driven study, in which subjects were randomized 1:1:1 to rivaroxaban 2.5 mg bid/ASA 100 mg od, or rivaroxaban 5 mg bid, or ASA 100 mg od."

Xevudy - sotrovimab - EMEA/H/C/005676/II/0004

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Submission of the final report from study PC-7831-0126 in order to fulfil the recommendation by the CHMP to submit an in vivo study in hamsters challenged with the UK (B.1.1.7) SARS-CoV-2 variant. This is a non-clinical study on the activity of sotrovimab against variants of concern from the UK, South Africa and Brazil."

Xevudy - sotrovimab - EMEA/H/C/005676/II/0007

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher,

"Update of sections 5.1 and 5.2 of the SmPC based on final results from study COMET-ICE (214367; VIR-7831-5001); this is a Phase II/III randomised, multi-centre, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalised patients."	
Zercepac - trastuzumab - EMEA/H/C/005209/II/0020 Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, "Submission of the final report from study HLX02-BC01 in order to fulfil REC/006. This is a double-blind, randomised, parallel-controlled, multicentre, international, phase 3 study to compare the efficacy, safety, and immunogenicity of HLX02 versus EU-sourced Herceptin in combination with docetaxel."	
WS2289 **OPDIVO- EMEA/H/C/003985/WS2289/0122** **Yervoy-EMEA/H/C/002213/WS2289/0099** Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, "To update sections 4.8 and 5.1 of the SmPC to include 7.5 years of minimum follow-up for all subjects based on addendum 04 Clinical Study Report for study CA209067; this is a phase 3 randomized, double-blind study of nivolumab monotherapy or nivolumab in combination with ipilimumab versus ipilimumab monotherapy in subjects with previously untreated, unresectable melanoma. The MAH has taken the opportunity to introduce minor editorial revisions in the SmPC."	
WS2304/G **Exviera- EMEA/H/C/003837/WS2304/0054/G** **Viekirax- EMEA/H/C/003839/WS2304/0066/G** AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, "Submission of the final reports from studies M14-423 (TOPAZ-1) and M14-222 (TOPAZ-II) listed as category 3 studies in the RMP for Viekirax and Exviera in order to fulfil MEA/018 for Viekirax and MEA/016 for Exviera. These are phase 3, open-label, multicentre, post-authorisation safety studies (PASS) to evaluate long-term outcomes with ombitasvir/ paritaprevir/ritonavir and	

dasabuvir with or without ribavirin (RBV) in adults with GT1 chronic HCV infection."

WS2312
Kisplyx-EMEA/H/C/004224/WS2312/0053
Lenvima-EMEA/H/C/003727/WS2312/0048
Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, "To update of SmPC sections 4.2 and 6.6 to include the option of administering the capsules as a suspension, including instructions for the administration and preparation of the suspension. The MAH also took the opportunity to include some editorial changes to the SmPC."

B.6.10. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0006
Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study B7471026 listed as a category 3 study in the RMP; this is a Phase III, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

JEMPERLI - dostarlimab - EMEA/H/C/005204/II/0013
GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study 4010-01-001 (GARNET) listed as a specific obligation in the Annex II; This is a single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumours. In addition, the MAH took the opportunity to update section E of Annex II. The RMP version 1.2 has also been submitted."

Jyseleca - filgotinib - EMEA/H/C/005113/II/0018

Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4, 4.6 and 5.1 of the SmPC in order to update information on fertility based on interim results from studies GLPG0634-CL-227 (MANTA Ray) and GS-US-418-4279 (MANTA) listed as a category 3 study in the RMP.
The Package Leaflet and Annex II are updated accordingly. The RMP version 4.1 has also been submitted."

Leqvio - inclisiran - EMEA/H/C/005333/II/0013
Novartis Europharm Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Kimmo Jaakkola, "Submission of the final report from ORION-3 study (CKJX839A12201E1 or MDCO-PCS-16-01) listed as a category 3 study in the RMP. This is an open label, active comparator extension trial to assess the effect of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C. The RMP version 2.0 has also been submitted."

MenQuadfi - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/005084/II/0018/G
Sanofi Pasteur, Rapporteur: Andrea Laslop, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.2, 4.5, 4.8 and 5.1 of the SmPC in order to add long-term antibody persistence at least 3 years after primary vaccination, immunogenicity and safety of a booster dose of MenQuadfi in adolescents, adults, and older adults, as well as co-administration data with meningococcal serogroup B vaccine in adolescents and adults, in order to fulfil ANX/002 and ANX/003 based on final results from studies MET59 and MEQ00066, respectively, listed as specific obligations in the Annex II. MET59 is a phase 3b, open-label, partially randomized, parallel-group, active-controlled, multi-center study evaluating the immunogenicity and safety of a booster dose of an investigational quadrivalent MenACYW conjugate vaccine in adolescents and adults, while MEQ00066 is a phase 3, two-stage, randomized, open-label, multi-center trial evaluating the safety and immunogenicity of a

single dose of MenACYW conjugate vaccine at least 3 years following initial vaccination with either Menomune vaccine or MenACYW conjugate vaccine in older adults. The Annex II and Package Leaflet are updated accordingly. The RMP version 1.1 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
NUBEQA - darolutamide - EMEA/H/C/004790/II/0012 Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Jan Neuhauser, "Submission of the final report of carcinogenicity study T104877-7 listed as a category 3 study in the RMP. This is a non-clinical study to assess the carcinogenic potential in mice. The study evaluates the effects of daily oral administration of darolutamide for a period of 6 months in tg-rasH2 transgenic mouse model. The updated RMP version 3.1 has also been submitted."	
QINLOCK - ripretinib - EMEA/H/C/005614/II/0004, Orphan Deciphera Pharmaceuticals (Netherlands) B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić, "Update of sections 4.2 and 5.2 of the SmPC in order to change posology recommendations in patients with hepatic impairment and update the description of pharmacokinetics based on final results from study DCC-2618-01-004; a Phase 1 study of the Pharmacokinetics, Safety, and Tolerability of Ripretinib in Subjects With Hepatic Impairment Compared to Healthy Control Subjects. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."	
Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0045 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the interim report from study GS-US-292-0106 listed as a category 3 study in the RMP. This is a Phase II/III, open-label study to evaluate of the pharmacokinetics, safety, tolerability, and antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen	

in HIV-1 infected antiretroviral treatment-naive adolescents and virologically suppressed HIV-infected children. The RMP version 8.1 has also been submitted."

Vumerity - diroximel fumarate - EMEA/H/C/005437/II/0005

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final report from study ALK8700-A301, A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis listed as a category 3 study in the RMP. This is a multicentre, open-label study to evaluate the long-term safety, tolerability, and treatment effect over time of DRF administered for up to 96 weeks in adult participants with RRMS.
The RMP version 1.1 has also been submitted."

WS2187
OPDIVO-
EMEA/H/C/003985/WS2187/0121
Yervoy-EMEA/H/C/002213/WS2187/0098

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.8 of the SmPC in alignment with the recommendations made by the CHMP to revise the pooling approach used to describe irARs and tabulated summaries of ADRs following II/0096. Individual study data included within this application has been previously reviewed by the CHMP. The updated Opdivo RMP version 29.0 and Yervoy RMP version 37.0 have also been submitted. The MAH took the opportunity to introduce editorial changes.
The Package Leaflet was updated accordingly."

WS2307
Rixathon-
EMEA/H/C/003903/WS2307/0062
Riximyo-
EMEA/H/C/004729/WS2307/0063

Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Anette Kirstine Stark, "Update of section 4.1 of the SmPC in order to include the rapid infusion regimen (90 minutes) for second and subsequent infusions in the label for patients with non-Hodgkin's lymphoma (NHL) or chronic

lymphocytic leukaemia (CLL) based on non-interventional PASS CGP2013ES01R and scientific literature.
The RMP version 7.0 has also been submitted."

WS2323
Juluca-EMEA/H/C/004427/WS2323/0045
Tivicay-EMEA/H/C/002753/WS2323/0081
Triumeq-EMEA/H/C/002754/WS2323/0106
ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Nathalie Gault, "Submission of the final report from study 200336 listed as a category 3 study in the RMP. This is a prospective, interventional pharmacokinetic and safety study of DTG/ABC/3TC in pregnant women. The summary of objective of this PASS study is to investigate the use of DTG during pregnancy and address the safety concerns of pregnant/breastfeeding women. The RMP versions 18.0, 20.0 and 4.0 for Tivicay, Triumeq and Juluca, respectively, have also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led
Besremi - ropeginterferon alfa-2b - EMEA/H/C/004128/II/0025
AOP Orphan Pharmaceuticals GmbH, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.1 for Besremi to revise safety concerns according to GVP Module V Rev.2."

PRAC Led
Cancidas - caspofungin - EMEA/H/C/000379/II/0078
Merck Sharp & Dohme B.V., PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 4.1 in order to remove safety concerns and align it with the EU GVP Module V (Revision 2)."

PRAC Led
Cotellic - cobimetinib - EMEA/H/C/003960/II/0027
Roche Registration GmbH, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann

Lodewijk Hillege, "Update of sections 4.4 and 5.1 of the SmPC in order to update information based on final results from study ML39302 listed as a category 3 study in the RMP in order to fulfil MEA/003.5; this is a non-interventional PASS study to investigate the effectiveness, safety and utilisation of cobimetinib and vemurafenib in patients with and without brain metastasis with BRAF V600 mutant melanoma under real world conditions. The RMP version 5.0 has also been submitted."

PRAC Led

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0051, Orphan

Roche Registration GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.8 of the SmPC in line with the SmPC Guideline following the recommendation by PRAC in the outcome for the signal assessment of non-overt disseminated intravascular coagulation (DIC) (EPITT no: 19711). The Package Leaflet is updated accordingly."

PRAC Led

Mycamine - micafungin - EMEA/H/C/000734/II/0047

Astellas Pharma Europe B.V., PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "To update Annex II and the RMP to version 23.0 to include the results of the non-interventional PASS as an Effectiveness Check of the Prescriber Checklist for Mycamine (micafungin) - 9463-PV-0002."

PRAC Led

SCENESSE - afamelanotide - EMEA/H/C/002548/II/0042, Orphan

Clinuvel Europe Limited, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 9.1 in order to update the allergy and hypersensitivity risk from potential to identified, following reported cases of positive allergy test results, confirming the causal association between the allergies to afamelanotide. Consequently, the RMP has been revised to reclassify the important potential risk Allergy and hypersensitivity to important identified risk."

PRAC Led

Stelara - ustekinumab -
EMEA/H/C/000958/II/0095
Janssen-Cilag International N.V., PRAC Rapporteur: Rhea Fitzgerald, PRAC-CHMP liaison: Jayne Crowe, "Submission of the final report from study PSOLAR (C0168Z03) listed as a category 3 study in the RMP. This is a Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics: PSOLAR. The RMP version 22.2 has also been submitted."

PRAC Led
WS2270
Vfend-EMEA/H/C/000387/WS2270/0147
Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To update the Annex II and RMP to version 6.0 to include the results from final clinical study report (CSR) following the completion of a non-interventional (NI) post-authorisation safety study (PASS), A1501103 "An Active Safety Surveillance Program to Monitor Selected Events in Patients with Long-term Voriconazole Use" - MEA091.
In addition, MAH is taking this opportunity to introduce editorial changes."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -
EMEA/H/C/004731/II/0004, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

Imlygic - talimogene laherparepvec -
EMEA/H/C/002771/II/0054, ATMP
Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo

Kymriah - tisagenlecleucel -
EMEA/H/C/004090/II/0062, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, "Submission of the final report from study CCTL019B2401 listed as a category 1 study in

the Annex II of the Product Information in order to fulfil ANX/007.3. This is a sub-analysis (PAES) to assess efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma based on data from the registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel. The Annex II is updated accordingly."

Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0031, Orphan, ATMP
Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

PRAC Led
Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0056, ATMP
Amgen Europe B.V., PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study 20120139 listed as a category 3 study in the RMP in order to fulfil MEA/004. This is a multicenter, observational registry study to evaluate the survival and long-term safety of subjects who previously received talimogene laherparepvec in Amgen or BioVEX sponsored clinical trials."

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2277
Herceptin- EMEA/H/C/000278/WS2277/0182
MabThera- EMEA/H/C/000165/WS2277/0192
Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2291/G
Ambirix- EMEA/H/C/000426/WS2291/0122/G
Twinrix Adult- EMEA/H/C/000112/WS2291/0157/G

Twinrix Paediatric-
EMEA/H/C/000129/WS2291/0158/G
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2301/G
M-M-RvaxPro-
EMEA/H/C/000604/WS2301/0117/G
ProQuad-
EMEA/H/C/000622/WS2301/0158/G
Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus,

WS2308/G
AZILECT-
EMEA/H/C/000574/WS2308/0090/G
Rasagiline ratiopharm-
EMEA/H/C/003957/WS2308/0022/G
Teva B.V., Lead Rapporteur: Bruno Sepodes

WS2310
Dovato-EMEA/H/C/004909/WS2310/0033
Triumeq-
EMEA/H/C/002754/WS2310/0107
ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson

WS2324/G
Suboxone-
EMEA/H/C/000697/WS2324/0053/G
Indivior Europe Limited, Lead Rapporteur: Janet Koenig

WS2337/G
Copalia-
EMEA/H/C/000774/WS2337/0126/G
Dafiro-
EMEA/H/C/000776/WS2337/0130/G
Exforge-
EMEA/H/C/000716/WS2337/0125/G
Novartis Europharm Limited, Lead Rapporteur: Thalia Marie Estrup Blicher, "C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107.
C.I.11.a - To update Annex II to reflect the fulfilment of Condition B, as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted

pursuant to Article 31 of Directive 2001/83/EC
for angiotensin-II-receptor antagonists (sartans)
containing a tetrazole group."

WS2338
Copalia HCT-
EMEA/H/C/001159/WS2338/0102
Dafiro HCT-
EMEA/H/C/001160/WS2338/0104
Exforge HCT-
EMEA/H/C/001068/WS2338/0101
Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher, "C.I.z - To update
section 4.9 of the SmPC, to implement the
wording related to the risk of non-cardiogenic
pulmonary oedema in amlodipine overdose,
following finalisation of procedure
PSUSA/00010434/202107."

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 18-21 July 2022 CHMP plenary:

Oncology	
Treatment of malignant glioma	The CHMP denied eligibility to PRIME and adopted the critical summary report.
First-line treatment of adult patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma in combination with PD-1 inhibitors	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Haematology - Hemostaseology	
Glenzocimab (ACT017) Treatment of acute ischemic stroke (SME)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Neurology	
Treatment of non-traumatic subarachnoid haemorrhage	The CHMP denied eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in July 2022 for September 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address